Prevalence of Cerebrospinal Fluid Abnormalities in First Episode Psychosis: A Systematic Review and Meta-analysis

Anjali Chandra, MD[1]; Laura Duque, MD[2] (0000-0002-6354-0720); Andrew Pines, MD, MA[1] (ORCID: 0000-0001-6968-2829); Anne Fladger, MLIS[3], Giovanna S. Manzano, MD, MSc[4] (ORCID: 0000-0002-9991-9222 Michael E. Benros, MD, PhD[5, 6] (ORCID: 0000-0003-4939-9465); Graham Blackman, MRCPsych, PhD (ORCID: 0000-0001-7025-8670)[7,8*]; Matthew L. Baum, MD, PhD, DPhil (ORCID: 0000-0001-6840-8932) [1*]

1: Department of Psychiatry, Brigham and Women's Hospital; Harvard Medical School, Boston, MA, USA
2: Division of Neuropsychiatry and Neuromodulation, Massachusetts General Hospital; Harvard Medical School, Boston, MA USA; Department of Psychiatry, University of Pennsylvania, Philadelphia, PA (Current Address)
3: Harvard Countway Library, Harvard Medical School, Boston, MA, USA
4: Department of Neurology, Mass General Brigham; Harvard Medical School, Boston, MA, USA
5: Copenhagen Research Centre for Biological and Precision Psychiatry, Mental Health Centre Copenhagen, Copenhagen University Hospital, Copenhagen, Denmark
6: Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
7: Department of Psychiatry, Warneford Hospital, University of Oxford, Oxford, United Kingdom
8. Department of Psychosis Studies, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom

*Joint senior authors

Contact Information:
Anjali Chandra, achandra@mgb.org, Department of Psychiatry, 60 Fenwood Road, Boston MA 02115

Word Count: 3,343

[Type here]

Key Points

Question: What is the prevalence of cerebrospinal fluid abnormalities in first-episode psychosis (FEP)?

Findings: In this systematic review and meta-analysis including 3,552 patients with FEP who systematically received a lumbar puncture, at least 6.5% had a clinically-relevant abnormality in the cerebrospinal fluid; prevalence of oligoclonal bands was 6.5%, pleocytosis was 3.2%, anti-NMDAR antibodies were 2.3%, and other anti-neuronal antibodies were 0.4%. Subgroup-analysis identified association between prior suspicion of secondary causes and prevalence-estimates.

Meaning: Lumbar puncture detects clinically-relevant abnormalities in FEP at a similar rate to brain MRI and may be especially informative when there is heightened suspicion for secondary psychosis.

53 Abstract

54 Importance
55 First-episode psychosis (FEP) may result from a variety of secondary etiologies, making lumbar
56 puncture (LP) for cerebrospinal fluid (CSF) investigations an important diagnostic consideration
57 in this context. However, the lack of high-quality evidence on the prevalence of clinically-
58 relevant CSF abnormalities hampers clinical consensus on when to pursue LP in FEP.
59

60 Objective
61 Determine a meta-analytic estimate of the prevalence of clinically-relevant CSF abnormalities in
62 FEP.
63

64 Data Sources
65 Electronic databases Ovid, Medline, Embase, PsychoINFO, and Web of Science were searched
66 from inception to October, 2024. References of included articles were also screened.
67

68 Study Selection
69 We included studies that performed LP on a cohort of FEP and reported results of clinically
70 available CSF analysis, enabling prevalence-estimates of abnormalities.
71

72 Data Extraction and Synthesis
73 Data was extracted following PRISMA and MOOSE guidelines. Pooled prevalences were
74 calculated by random-effects models. Moderators were tested using meta-regression analysis,
75 and heterogeneity assessed by I^2 index.
76

77 Main Outcomes and Measures
78 Prevalence of CSF abnormalities, focusing on clinically-relevant markers and number needed to
79 assess (NNA).
80

81 Results
Thirty-eight papers comprising 3,552 FEP patients who underwent LP were included, allowing
calculation of prevalence-estimates for 12 CSF abnormalities. Of clinically-relevant
abnormalities, the prevalence of CSF-restricted oligoclonal bans (OCB2) was 6.5% (95% CI 3.1-
10.8, NNA 15), pleocytosis was 3.2% (95% CI 2.1-4.4, NNA 31) and anti-NMDAR antibodies
was 2.3% (95% CI 0.1-6.4, NNA 43). Subgroup analysis showed that anti-neuronal antibodies
were mainly detected in studies that selected patients with high suspicion of secondary causes
and were low in studies which excluded patients with a high index of suspicion of a secondary
cause, based on clinical and ancillary testing. OCBs and pleocytosis also had higher prevalence
in the high-suspicion subgroup but were still detected at prevalence even in the low-suspicion
subgroup.
92

93 Conclusions and Relevance
The meta-analytic estimate of the prevalence of the most common clinically relevant CSF
abnormality was 6.5%, which is similar to the prevalence of finding any clinically-relevant

radiologic abnormality with an MRI brain. Subgroup-analysis supports the usefulness of
methods to estimate the pre-LP probability of clinically-relevant CSF abnormalities, albeit these
methods are better applied for some abnormalities (CNS-reactive antibodies) than others
(OCB2).

Introduction

Approximately 3-4 of 100 people will experience a first episode of psychosis (FEP) in their lifetime[1]. Careful clinical assessment and use of ancillary diagnostic procedures is used to identify the proportion of these cases that have secondary causes, including toxic, neurologic, metabolic, or autoimmune dysfunction, which carry distinct treatment and prognostic implications.[2] Because some causes of secondary psychosis may yield detectable abnormalities in the cerebrospinal fluid, lumbar puncture (LP) is sometimes considered in the evaluation of FEP. Lumbar puncture (LP) is a well-established general medical procedure with a high sensitivity and specificity for detection of neuroinflammation [3–6] , but its clinical utility remains uncertain for the evaluation of FEP. While many posit that LP should be restricted to cases where there exists a high suspicion of neuroinflammation (i.e., autoimmune encephalitis), supported by clinical red flags or abnormalities on MRI brain, EEG, or serum auto-antibody testing[3,4,6–9], others support incorporating LP into routine testing of FEP[10].

The lack of international consensus pertaining to the role of LP in the evaluation of FEP is in part fueled by a dearth of high-quality estimates of the prevalence of CSF abnormalities in FEP. Reported prevalence of clinically-relevant CSF findings[3,8] are based on individual studies that have small sample sizes with limited power. To date, there has been no attempt to generate a comprehensive meta-analytic estimate of the prevalence of CSF abnormalities in FEP.

In this study, we sought to generate the largest, most comprehensive meta-analytic estimate of the prevalence of CSF abnormalities in FEP. We draw from a pool of studies where an entire study sample received a LP, thus enabling prevalence-estimates. We also sought to explore how the prevalence of CSF abnormalities varies based on the *a priori* suspicion of an underlying secondary cause by grouping studies according to whether they were based on: (1) unselected FEP patients recruited solely on the basis of first-episode psychosis, regardless of whether there was a clinical suspicion for a secondary cause, (2) FEP patients with a high-clinical suspicion for a secondary cause and (3) FEP patients with low-clinical suspicion for a secondary cause. Although we quantified all CSF-abnormalities, we also sought to highlight certain abnormalities with particular clinical relevance.

Methods

We performed a systematic review and meta-analysis according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) and Meta-Analysis of Observational Studies in Epidemiology (MOOSE) guidelines[11–13]. The study was prospectively registered on PROSPERO (CRD42024577715). A comprehensive search of Ovid MEDLINE, Embase, Web of Science, and PsychInfo was conducted up to October 2024. References of included articles and reviews were also searched. After the automated removal of duplicate papers, a title and abstract screen was performed by two independent raters, followed by a full-text review. For further details on the search strategy, eligibility criteria, and method for data

140 extraction, quality assessment, heterogeneity assessment, and sensitivity analyses, see
141 eMethods.
142
Outcomes
Only CSF tests that were clinically available through Mayo Clinic Laboratories and Associated
Regional and University Pathologists (ARUP) Laboratories were included. For consistency
across studies, a common threshold was used to define an abnormal test result based on
established, aligned cutoff values used by these two laboratories. For example, studies varied in
the cutoff used for pleocytosis; we used >5 WBCs, which is the cut-off established by Mayo
Clinic laboratories. Studies that only reported research-grade assays and continuous variables
(that did not enable prevalence-estimates) were excluded. We performed meta-analytic
estimates for any CSF tests that were reported by ≥3 studies. A subset CSF abnormalities were
highlighted as clinically-relevant based on expert clinical opinion[4]: pleocytosis, OCB2, and
antibodies associated with autoimmune encephalitis (anti-NMDAR antibodies, GAD65
antibodies, LGI1 antibodies, AMPAR antibodies, CASPR antibodies, GABAR antibodies, and Yo
antibodies)
156
Statistical Analysis
The overall prevalence of CSF abnormalities amongst FEP patients was calculated within each
study along with a 95% confidence interval. Meta-analytic estimates were calculated for
abnormalities that were reported in 3 or more studies. A random-effects model using the
DerSimonian and Laird method was performed[14]. We opted to use a random-effects model as
we anticipated methodological heterogeneity between studies. All analyses were performed
using R 4.4.1 with meta-analyses performed using meta, metafor and metainf. Number needed
to assess (NNA) for each of the abnormalities as defined by 1/proportion. We aimed to calculate
relative risk of any CSF abnormalities that were reported in 3 or more studies that also had
healthy controls. Additional details regarding statistical methods are included in eMethods.
167
168
Subgroup Analyses
Where there were sufficient data (i.e. 6 or more studies)[15], we performed subgroup analysis of
3 cohort types: (1) Unselected FEP cohorts that included all individuals with first-episode
psychosis, irrespective of clinical suspicion for a secondary cause, (2) cohorts that selected for
patients with a high-clinical suspicion for a secondary cause and (3) studies that specifically
excluded patients with high-clinical suspicion for secondary causes. In addition, meta-regression
was used to examine the effect of age and publication year, provided that data from at least 6
studies were available[15].
177
178

179 Results

<u>Search Results and Study Selection</u>
The search strategy resulted in 2,476 publications. After the removal of duplicates, screening of
title and abstracts, 257 papers were reviewed in full. eFigure 1 shows the PRISMA flow chart
and additional details are in eMethods.

<u>Study Characteristics</u>
There were 38 eligible papers[4,6,11–50]; reporting findings from 33 cohorts identified. See eTable 1
in Supplement 1 for detailed study characteristics. Studies were published between 1987 and
2024, reporting a total sample of 3,680 FEP patients. One paper was excluded due to high risk
of bias[40] resulting in 37 papers with 3,552 unique patients. Only 3 studies reported healthy
control comparison groups[17,32,50]. Studies were conducted in the following regions: Europe
(n=24), North America (n=5), and Asia (n=4). While all patients within these studies received an
LP, studies selected their patient population in different ways. Eleven cohorts excluded patients
with suspicion for secondary causes for FEP (e.g. suspected autoimmune encephalitis), six
selected for patients with a high suspicion for secondary causes, two studies had cohorts that
were separable into a discrete high-suspicion group and discrete low-suspicion group, and the
remaining 13 studies were based on an undifferentiated sample. Studies were not uniform in
how they determined high or low suspicion for secondary psychoses with different clinical or
ancillary testing used (see eTable 3 for details of individual methods).

<u>Participant Characteristics</u>
FEP sample sizes ranged from 13 to 332. Mean age ranged from 20-49 years. The median
proportion of female was 41.9% (IQR 19.6 to 55.9). Duration of psychosis ranged from 4 to
103.8 weeks. Practice settings included: inpatient psychiatric unit at an academic medical
center (19), inpatient psychiatry and neurology unit within a general hospital, research ward or
unspecified setting (8), mixed setting spanning inpatient units, a neurological center, and
outpatient settings (3), acute (emergency) psychiatry (2), and finally, academic medical center
(1).

<u>Characteristics of CSF analysis</u>
Assays reported in 3 or more studies were CSF IgG index, protein, OCBs Type 2, Type 3, Type
4, and Type 5, Cell Count (both studies using the more stringent WBC >5, and studies using
WBC≥5), anti-NMDAR antibodies, GAD65 antibodies, LGI1 antibodies, AMPAR antibodies,
CASPR antibodies, GABAR antibodies, and Yo antibodies.

<u>Quality Assessment and Risk of Bias</u>

Twenty-four cohorts were low risk of bias, 8 were medium risk of bias, and 1 was high risk of
bias[40] (and was therefore excluded).

<u>Prevalence of clinically relevant CSF abnormalities</u>
Pleocytosis (defined as > 5WBCs) (Figure 1a) had a prevalence of 3.2% (95% CI 2.1-4.4,
n=1087), a number needed to assess (NNA) of 32, and an I^2 of 0.0%. OCBs restricted to the

CSF (Type 2)[56] (Figure 1b) had a prevalence of 6.5% (95% CI 3.4-10.6, n=1452100), a NNA of
15, and an I^2 of 84.7%. Anti-NMDAR antibodies (Figure 1c) had a prevalence of 2.3% (95% CI
0.1-6.4, n=1279), a NNA of 43, and an I^2 of 87.1%. Yo antibodies (eFigure 2a) had a
prevalence of 0.4% (95% CI 0 to 1.7, I^2 14.3%, n=367). GAD65, LGI1 antibodies, AMPAR,
CASPR, and GABAR antibodies (eFigure 2) all had a prevalence of 0% (95% CI 0 to 0.3, I^2
0.0%, n=507 [GAD65], n=359 [LGI1], n=395 [AMPAR and GABABR], n = 365 [CASPR]) in the
CSF.
228
<u>Prevalences of other CSF abnormalities (eFigure 2)</u>
Elevated CSF IgG index had a prevalence of 5.4% (95% CI of 1.1 – 11.6, I^2 78.6%, n=526).
Type 3 OCBs had a prevalence of 6.6% (95% CI 4.3 – 9.3, I^2 41.7%, n=717), Type 4 OCBs had
a prevalence of 9.6% (95% CI 3.1 – 19.0, I^2 92.4%, n=717), and Type 5 OCBs had a prevalence
of 0% (95% CI 0 - 0.4, I^2 0.0%, n=509). Prevalence of elevated albumin was 18.7% (95% CI
14.9 - 22.7, I^2 51.2%, n=1,004) and elevated total protein was 18.7% (95% CI 9.7 to 29.5, I^2
93.5%, n = 1,194).
236
237 <u>Relative Risk of CSF Abnormalities</u>
238 Relative risk was not calculated as there were ≤ 3 study cohorts with healthy control groups
239 reporting values for any given test[17,32,50].
240
241 **Figure 1**. Forest plots of clinically relevant CSF abnormalities in first-episode psychosis
242 A. Prevalence of Pleocytosis (WBC>5)

Study	Cases	Total	Prev(%)	95% C.I.
Lopes 2024	1	68	1.5	[0.7; 8.3]
Guasp 2021	2	105	1.9	[0.7; 6.8]
Jeppesen 2022	2	104	1.9	[0.5; 6.7]
Endres 2015	6	179	3.4	[1.4; 7.0]
Gine-Serven 2022	3	95	3.2	[1.2; 9.0]
Campana 2022	11	314	3.5	[1.7; 5.9]
Oviedo-Salcedo 2018	6	124	4.8	[2.1; 10.1]
Rattay 2021	5	98	5.1	[2.0; 11.2]
Total			3.2	[2.1; 4.4]

Abnormal Cell Count WBC cutoff >5(%)

243 Heterogeneity: $\chi_7^2 = 3.33$ ($P = .85$), $I^2 = 0.0\%$, $\tau^2 = 0$

251   B. Prevalence of Oligoclonal Bands Type 2 (%)

Study	Cases	Total	Prev(%)	95% C.I.
Runge 2022	1	100	1.0	[0.3; 5.6]
Maurus 2023	3	121	2.5	[1.0; 7.2]
Kruse 2015 Group B	0	8	0.0	[2.6; 34.2]
Campana 2023	5	171	2.9	[1.2; 6.6]
Campana 2022	7	217	3.2	[1.5; 6.4]
Runge 2021	1	40	2.5	[0.0; 11.2]
Endres 2024	6	161	3.7	[0.0; 3.9]
Hinotsu 2022	7	151	4.6	[2.2; 9.2]
Endres 2015	10	180	5.6	[2.9; 9.8]
Rattay 2021	5	89	5.6	[2.5; 12.5]
Lopes 2024	5	68	7.4	[2.8; 15.8]
Oviedo-Salcedo 2018	18	123	14.6	[6.3; 19.6]
Kruse 2015 Group A	9	13	69.2	[42.8; 85.2]
Srikanth 1994	8	10	80.0	[49.1; 91.4]
Total			6.5	[3.1; 10.8]

Oligoclonal Bands (OCB2) Prevalence (%)

252   Heterogeneity: $\chi^2_{13} = 85.21$ ($P < .001$), $I^2 = 84.7\%$, $\tau^2 = 0.0137$

253   C. Prevalence of anti-NMDAR Antibodies (%)

Study	Cases	Total	Prev(%)	95% C.I.
Guasp 2021	0	105	0.0	[0.0; 3.5]
Jeppesen 2022	0	104	0.0	[0.0; 3.6]
Bien 2021	0	103	0.0	[0.0; 2.4]
Rattay 2021	0	98	0.0	[0.0; 3.8]
Gine-Serven 2022	0	95	0.0	[0.0; 3.9]
Endres 2022	0	89	0.0	[0.0; 0.0]
Theorell 2021	0	71	0.0	[0.0; 2.9]
Rauber 2021	0	59	0.0	[0.0; 2.6]
Runge 2021	0	40	0.0	[0.2; 9.4]
Endres 2015	1	125	0.8	[0.0; 3.7]
Maier 2024	4	254	1.6	[0.0; 0.1]
Lopes 2024	4	68	5.9	[2.5; 14.3]
Tang 2019	3	15	20.0	[8.8; 45.4]
Kruse 2015 Group B	2	8	25.0	[8.9; 58.6]
Steiner 2013	2	6	33.3	[14.4; 67.5]
Kelleher 2020	1	2	50.0	[20.2; 79.8]
Restrepo-Martinez 2020	14	24	58.3	[39.1; 74.9]
Kruse 2015 Group A	8	13	61.5	[36.3; 80.5]
Total			2.3	[0.1; 6.4]

NMDA Antibody Prevalence (%)

Heterogeneity: $\chi^2_{17} = 132.11$ ($P < .001$), $I^2 = 87.1\%$, $\tau^2 = 0.0247$

Figure 1 Legend: The size of each box is proportional to the weight of the study in relation to the pooled
prevalence estimate (as calculated by a random effects model in the final row of the figure).

Columns: Cases – number of FEP patients with that particular CSF abnormality, Total – total number of
FEP patients tested, Prev (%) – raw prevalence of abnormality in that study, C.I. – Confidence Interval.

Kruse 2015 Group A – patients who had serum positivity for anti-NMDAR antibodies. Kruse 2015 Group
B- all patients who had serum studies regardless of NMDAR positivity

<u>Subgroup Analyses (Figure 2)</u>
The prevalence of pleocytosis (WBC>5) was 3.1% (95% CI 1.9-4.6, k=5, I^2 0%, n=742) amongst
studies that excluded cases with clinical suspicion of secondary causes. Subgroup estimates
could not be made for the undifferentiated or high clinical suspicion subgroups because each
had less than 3 studies.
269
270 The prevalence of OCB2 was 9.7% (95% CI 3.1-18.9, k=6, I^2 89.7%, n=680) amongst studies
271 that excluded cases with clinical suspicion of secondary causes. Prevalence was 3.6% (95% CI
272 2.2- 5.3, k=5, I^2 14.6%, n=713) amongst studies that did not include or exclude cases based on
273 clinical suspicion of secondary causes. Prevalence was 13.8% (95% CI 0.6-36.4, k=4, I^2 88.3%,
274 n=178) for the high clinical suspicion subgroup.
275
276
277 The prevalence of anti-NMDAR antibodies was 0% amongst studies that excluded cases with
278 clinical suspicion of secondary causes (95% CI 0.0-0.0%, I^2 0%, n=668), was 1.2% (95% CI 0.3
279 to 2.6, k=3, I^2=0%, n=452) amongst studies that did not include or exclude cases based on
280 clinical suspicion of secondary causes, and was 23.1% (95% CI 3.7-50.2, k=7, I^2=92.7%,
281 n=230) in the subgroup with high clinical suspicion of secondary causes.
282
283
284 **Figure 2** Forest plots of subgroup analysis of clinically relevant lumbar puncture abnormalities
285 in First-Episode Psychosis, based on clinical suspicion of secondary causes
286
287 A. Prevalence of Pleocytosis (WBC>5) in subgroups based on clinical suspicion of secondary
288 causes

291 B. Prevalence of Oligoclonal Bands in subgroups based on clinical suspicion of secondary
292 causes

C. Prevalence of anti-NMDAR antibodies in subgroups based on clinical suspicion of secondary
causes

The size of each box is proportional to the weight of the study in relation to the pooled prevalence
estimate (as calculated by a random effects model in the final row of the figure).

Columns: Cases – number of FEP patients with that particular CSF abnormality, Total – total number of
FEP patients tested, Prev (%) – raw prevalence of abnormality in that study, C.I. – Confidence Interval.

Kruse 2015 Group A – patients who had serum positivity for anti-NMDAR antibodies. Kruse 2015 Group
B- all patients who had serum studies regardless of NMDAR positivity

<u>Influence of Potential Effect-Modifiers and Publication Effects</u>

Meta-regression found year of publication did not have a significant effect on pleocytosis (p =
0.46) but was associated with reduced OCB2 (p < 0.0001), and Anti-NMDAR antibodies (p <
0.005). No statistically significant associations were identified for age for pleocytosis (p = 0.82),
OCB2 (p = 0.27), or anti-NMDAR antibodies (p = 0.93). Leave one out analyses showed general
stability of pooled prevalence and heterogeneity estimates, suggesting that the overall results
are not driven by any individual dataset (Fig. 4A). Funnel plots (Fig. 4B) showed no significant
asymmetry by Eggers test for pleocytosis (p = 0.71) but did show significant asymmetry for
OCB2 and anti-NMDAR antibodies (*p* < 0.0001), suggesting the latter may have small-study
effects or publication bias (e.g. small studies tended to have higher prevalence of anti-NMDAR
antibodies), or that studies included populations with different *a priori* risks of OCB2 or anti-
NMDAR antibodies.

[Type here]

Figure 4. Publication Effects. A) Leave one out analyses show influences of individual studies
B) Funnel plots show potential for small study effects, publication bias, or differences in baseline
characteristics in studies.

339 Discussion

We report the largest comprehensive meta-analytic prevalence-estimates of cerebrospinal fluid
(CSF) abnormalities in patients with first-episode psychosis (FEP).

The most prevalent clinically-relevant CSF finding across the included studies was OCB2
(6.5%), followed by pleocytosis (3.2%), anti-NMDAR antibodies (2.3%) and other anti-neuronal
antibodies (0.4%). The presence of pleocytosis, CSF auto-antibodies[4,57], or OBC2 may alter
prognosis or management in the appropriate clinical context, including consideration of further
ancillary testing or immunomodulatory treatments that would not form part of the normal
treatment pathway of a primary psychotic disorder[58,59]. At 6.5% prevalence, the prevalence of
OCB2 in FEP is comparable to the prevalence of a clinically relevant abnormality on MRI brain
based on recent meta-analytic estimates[60]. As another benchmark for reference, CT head has
an estimated diagnostic yield close to 0% in the workup of FEP[61]. The prevalence of OCBs for
cryptogenic epilepsies is 8% (for which LP is sometimes pursued) and 2% in patients with
acute-Covid related neurological symptoms, suggesting that our finding of 6.5% is notable and
would merit further investigation into its implications for the clinical workup and management of
FEP.

The current initial workup for FEP varies between hospital systems but often includes serum
laboratory testing and in some centers neuroimaging and EEG[62]. Though lumbar puncture is not
often included as a part of this initial workup, outside of a few hospital systems in Germany (as
per the Freiburg diagnostic protocol for FEP[63], it is often recommended in cases with a
heightened suspicion of autoimmune encephalitis based upon clinical history, exam, and/or
other testing results[3]. Subgroup analyses suggested that including or excluding patients with
high clinical suspicion for secondary psychosis makes a substantial difference to the detection
of anti-neuronal antibodies. Prevalence of anti-NMDAR antibodies was an order of magnitude
higher in the high-clinical suspicion group (23.1%) than an undifferentiated FEP group (1.2%),
and were undetectable in samples which excluded high-suspicion individuals. These
observations suggest that thorough clinical assessment is important, and LP might be viewed as
a critical diagnostic tool in people with FEP and high suspicion for secondary causes; an
important technical caveat being, however, that the methods studies used to define high
suspicion differed (see supplementary materials).

In contrast, though the prevalence of OCBs and pleocytosis was modestly higher in the high-
clinical suspicion group (13.8%) than in an undifferentiated FEP group (3.6%), studies that
excluded patients considered high risk of a secondary psychosis did not have lower prevalence
(9.7%); this suggests that the clinical protocols for determining low suspicion groups did not
effectively exclude some clinically relevant CSF abnormalities.

Our results also raise the question of what should be the clinical role of LP in FEP. Although the
prevalence of CSF abnormalities in FEP provides critical information, there are other important
factors to consider prior to determining the clinical place of LP in FEP such as safety,
acceptability, cost, and accessibility. LPs are generally safe procedures, even amongst other

vulnerable populations such as patients with Alzheimer's dementia[65]. The most common
iatrogenic risk is post–LP headache[66,67] and the risk of more serious complications is low at
0.20%[68]. A recent meta-analysis found that post-LP headache prevalence can be reduced to
4% with the incorporation of novel methods (i.e., atraumatic needle) as compared to 11% with
the conventional method (i.e., traumatic needle)[69]. Acceptance rates of LP amongst patients
with psychosis have been estimated at 66%, with acceptance influenced by factors such as
informative patient education, perceived risk of invasiveness, and perceived necessity[70,71]
Formal cost-benefit analyses of LP in FEP are lacking, though there has been one USA-based
study on cost-effectiveness of serum testing for anti-NMDAR antibodies in all cases of FEP to
select high-risk individuals needing LP and CSF analyses for anti-NMDAR antibodies[72].
Accessibility to LP is geographically variable, and patient factors such as having MRI-
incompatible implanted device(s) may preclude the accessibility of alternative imaging-guided
approaches.

<u>Strengths and Limitations</u>

A meta-analytic estimate transcends the limits of small individual sample size and study-design
variation, thus rising to the highest category of quality by the Oxford Centre for Evidence-Based
Medicine criteria (cebm.net). A meta-analysis of prevalence of blood brain barrier disruption in
N=531 patients with recent onset psychosis was recently reported[73], outside the dates of our
literature search; our meta-analysis has a combined sample nearly seven times larger than this,
focuses on the most clinically relevant CSF abnormalities, and has a more comprehensive
inclusion of clinical abnormalities. Our study's general strengths include its comprehensive
search strategy, adherence to PRISMA and MOOSE guidelines, and rigorous assessment of
heterogeneity and publication bias. Subgroup analyses allowed us to explore potential
moderators and sources of heterogeneity.

However, several limitations also warrant consideration. First, most studies did not include
healthy controls, preventing us from being able to explore the relative risk of CSF abnormalities
in psychosis. Second, heterogeneity across studies was substantial, with I² values exceeding
80% for OCBs and anti-NMDAR antibodies, likely reflecting variability in the included patient
populations, diagnostic criteria, and laboratory methods. Moreover, though our study assembled
a comparatively large sample size, the low prevalence of some abnormalities still resulted in
wide confidence intervals, consistent with previous meta-analyses on prevalence of anti-
NMDAR antibodies in serum[74]. Our Egger plot analysis also suggested possible small-study
effects, cohort differences, or publication bias of some abnormalities.

The majority of studies were from a population representative of patients with FEP, but certain
studies had selected patient populations that may be influencing prevalence-estimates. For
example, one study[21] examined only COVID-19 positive patients and another study[37], included
patients with high clinical suspicion for "organic" psychosis between 1998 and 2016, but
thereafter included all patients with psychosis. Notably, year of publication was associated with
declining prevalence of OCBs, pleocytosis and anti-NMDAR antibodies, potentially reflecting
advances in diagnostic specificity or changes in patient selection over time. Sometimes we were
able to detect differences in reporting; for example, studies differed on the WBC cutoff to define

pleocytosis, and we were able to harmonize the cutoff (in this case to greater than 5 WBCs).
Other methodological differences in how studies conducted CSF testing were also not able to
be accounted for in this study, for example, there increasing attention is being paid to the effect
of different methods of anti-neuronal antibody ascertainment[75,76] and studies included here did
not use identical methods.

Importantly, as studies did not consistently report individual patient-specific CSF abnormalities,
we are not able to generate a pooled prevalence-estimate of likelihood of having *any (i.e at least*
one) clinically relevant abnormality. Such information would be informative in practice, for
example, as an individual may have a   pathogenic process that is evident by detecting
abnormality in one of several possible tested components, i.e., a pathogenic
neuroimmunological process may show itself in a particular individual with the presence of an
autoantibody, inflammatory routine studies, or elevated oligoclonal bands, but not necessarily all
of the abnormalities or multiple of the abnormalities concurrently. The conservative estimate of
the prevalence of *at least one* clinically relevant CSF abnormality is 6.5%, the rate of OCB2, but
the true prevalence of having *any* abnormality is likely higher (e.g. as some people might have
pleocytosis but not OCB2s).

Finally, our study was limited to a binary definition of most variables as abnormal or not, and
any additional information from magnitude of the abnormality was not captured. For example,
for anti-CNS antibodies, many studies reported only presence or absence, though the antibody
titer is often important for interpretation.

Conclusion and perspectives

This meta-analysis found the prevalence of clinically-relevant CSF abnormalities in FEP to be at
least 6.5%, and therefore comparable to the prevalence of clinically relevant imaging
abnormalities via brain MRI. The prevalence of clinically-relevant CSF abnormalities was higher
amongst patients with a high clinical suspicion for secondary causes. The findings underscore
the need for continued consideration of LP as a diagnostic approach for the evaluation of FEP,
and this meta-analytic estimate of CSF abnormality prevalence provides current state-of-the-art
evidence to guide the decision whether to pursue LP. Having established the prevalence of
clinically relevant CSF abnormalities in FEP, further evidence is needed to determine the clinical
utility of lumbar puncture in this patient group, however. This includes research on its diagnostic
impact, treatment implications, effects on clinical outcomes, acceptability to patients and
clinicians, and cost-effectiveness. Moreover, further studies are needed to compare
effectiveness of different diagnostic algorithms for secondary psychoses and to report the
clinical outcomes of patients with CSF abnormalities (especially those without an identified,
clinically well-defined auto-antibody), including response to targeted treatments.

Supplement

eMethods

Search Strategy

The search was conducted in a stepwise fashion: (1) electronic databases were searched from
inception until October 2024, and (2) the references of eligible articles and reviews were
manually reviewed. A title and abstract screen was performed prior to full article review to
confirm eligibility. Databases included were Ovid, MEDLINE, Embase, PsychINFO Web of
Science using the search terms that were developed in consultation with a research librarian
(AF). Two researchers (A.C., L.D., A.P., M.B) independently performed the title and abstract
screen and full text review in parallel. Articles with consensus approval between both raters
were included. Discrepancies were resolved by an independent rater (GB).
477
Search Terms
OVID Medline
Schizophrenia/di OR Psychotic Disorders/di OR (psychotic* OR psychosis or
schizophren*).ti,ab,kw,kf
AND
exp cerebrospinal fluid/ OR exp spinal puncture/ OR (cerebrospinal fluid OR CSF OR spinal
puncture* OR lumbar puncture*).ti,ab,kw,kf
AND
Diagnosis/ OR (diagnos*).ti,ab,kw,kf
Embase
'schizophrenia'/mj OR 'psychosis'/mj OR (psychotic* OR psychosis or schizophren*):ti,ab,kw
AND
'cerebrospinal fluid'/exp OR 'lumbar puncture'/exp OR ('cerebrospinal fluid' OR CSF OR 'spinal
puncture*' OR 'lumbar puncture*'):ti,ab,kw
AND
'diagnosis'/mj OR (diagnos*):ti,ab,kw
Web of Science
TI=(psychotic* OR psychosis or schizophren*) OR AB=(psychotic* OR psychosis or
schizophren*) OR AK=(psychotic* OR psychosis or schizophren*)
AND

TI=("cerebrospinal fluid" OR CSF OR "spinal puncture*" OR "lumbar puncture*") OR
AB=("cerebrospinal fluid" OR CSF OR "spinal puncture*" OR "lumbar puncture*") OR
AK=("cerebrospinal fluid" OR CSF OR "spinal puncture*" OR "lumbar puncture*")
AND
TI=(diagnos*) OR AB=(diagnos*) OR AK=(diagnos*)
PsychInfo
(DE "Schizophrenia" OR DE "Acute Schizophrenia" OR DE "Catatonic Schizophrenia" OR DE
"Paranoid Schizophrenia" OR DE "Process Schizophrenia" OR DE "Schizoaffective Disorder"
OR DE "Schizophrenia (Disorganized Type)" OR DE "Schizophreniform Disorder" OR DE
"Undifferentiated Schizophrenia") OR TI (psychotic* OR psychosis OR schizophren*) OR AB
(psychotic* OR psychosis or schizophren*)
AND
DE "Cerebrospinal Fluid" OR TI ("cerebrospinal fluid" OR CSF OR "spinal puncture*" OR
"lumbar puncture*") OR AB ("cerebrospinal fluid" OR CSF OR "spinal puncture*" OR "lumbar
puncture*")
AND
MM "Diagnosis" OR TI (diagnos*) OR AB (diagnos*)
515
516
<u>Eligibility Criteria</u>
Eligibility criteria were FEP patients (including patients with psychosis possibly due to a general
medical condition, primary psychiatric disorder, and unspecified psychosis) for whom clinically
available CSF testing had been reported to allow for the calculation of prevalence-estimates.
Studies were included if they performed one or more clinically available CSF analyses, defined
as being in the laboratory manual of Mayo Clinic or ARUP. Where there were overlapping
samples, the study with the larger sample was utilized. There were no age or language
restrictions. Excluded from the analysis were studies with insufficient data to permit calculation
of prevalence-estimates, post-mortem studies, case reports or case series.
526
<u>Data Extraction and Encoding</u>
Data extraction was independently performed in Covidence systematic review software (Veritas
Health Innovation, Melbourne, Australia. Available at www.covidence.org) by four researchers
(AC, MB, LD, AP) using a piloted standardized form with a fourth researcher (GB) resolving any
discrepancies. For each study, information on the study characteristics, sample, and CSF
handling processes was also extracted. Where reported, healthy control data was also extracted
to calculate risk ratios. For categorizing of subgroups and modeling purposes, certain
assumptions were made and the following *ad hoc* criteria were applied for borderline cases: 1) if
a study only excluded patients with known dementia (but not other causes of psychosis), they
were coded as an undifferentiated sample, 2) if a cohort study changed inclusion criteria mid-
study from including only cases with clinical high-suspicion for secondary cause to including all
FEP (i.e. undifferentiated FEP), they were coded as undifferentiated FEP provided >80% of the
cohort was collected during the period where LP was performed for all FEP. If not, they were
coded as high-suspicion subgroups. This grouping was done *post hoc*.
541
In our review of studies, we found that there were several from one research group that had
nested, partially overlapping samples: Endres 2015, 2017, 2020, 2021, 2022, and 2024. All of
these studies had patient samples that partially overlapped with Endres 2020, and each study

had some overlap with the closest chronological study, but Endres 2015 appeared to have no
sample overlap with 2022 and 2024. As such we chose to include Endres 2015 and Enders
2022+2024 (as a merged cohort extracting the largest sample for each CSF test), as this
resulted in the largest non-overlapping patient cohort from the overlapping group. However, an
alternative strategy would have been to include Endres 2020 only, as this study had the largest
overall patient cohort of any individual study in the overlapping group; we re-conducted the
analysis with this second method of handling this complex overlapping sample, and report a
comparison of values in eTable 4.
553
554
555 Quality Assessment
556 A 10-item risk of bias assessment tool was utilized (Hoy et al. 2012). Studies were categorized
557 based on a summative score and categorized as high (0-3), moderate (4-6), or low (7-10) risk of
558 bias[77]. Those deemed as having high risk of bias were excluded.
559
560 Heterogeneity Assessment
561 The I^2 index was used to assess heterogeneity. Low degree of heterogeneity was defined as an
562 I^2 of <25%, moderate heterogeneity was 25 to 75%, a high degree heterogeneity was defined as
563 75 to 100%. A Baujat plot was also generated to assess heterogeneity and influence.
564
Sensitivity Analyses
Sensitivity analyses were performed to explore the robustness of findings, including the effects
of studies with a moderate risk of bias. Influencer diagnostics were performed based on leave
one out analyses to identify studies with excessive influence on the pooled prevalence-
estimates or heterogeneity. Risk of publication bias was assessed via visual inspection (for
asymmetry) of Egger plots[78] for main outcomes.
571
572 Use of AI or LLM
573 Chat GPT 5.0 was used to resolve errors when adapting the leave-one-out sensitivity analysis
574 script from Blackman et al. 2023[79] that arose due to changes in the meta package in the most
575 recent version of R. AI was not used for the generation of any of the images, plots or original
576 analyses, or elsewhere in the manuscript.
577

578 # eFigures

579 ## eFigure1 PRISMA flow diagram

22nd August 2025

582 ## eFigure2. Prevalence-estimates of other CSF abnormalities

583 ### eFigure 2a: Prevalence of Anti-Yo antibodies

585 ### eFigure 2b: Prevalence of abnormal IgG antibody index

587 ### eFigure 2c: Prevalence of Glycine antibodies

Study	Cases	Total	Prev(%)	95% C.I.	
Bien 2021	0	103	0.0	[0.0; 3.6]	
Rauber 2021	0	59	0.0	[0.0; 6.1]	
Random effects model			0.0	[0.0; 1.1]	

Heterogeneity: $I^2 = 0.0\%$, $\tau^2 = 0$, $\chi_1^2 = 0.04$ ($p = 0.8477$)

Glycine antibodies(%)

589 ### eFigure 2d. Prevalence of GABAB receptor antibodies

Study	Cases	Total	Prev(%)	95% C.I.	
Endres 2015	0	125	0.0	[0.0; 3.0]	
Bien 2021	0	103	0.0	[0.0; 3.0]	
Lopes 2024	0	68	0.0	[0.0; 5.6]	
Rauber 2021	0	59	0.0	[0.0; 6.1]	
Runge 2021	0	40	0.0	[0.1; 9.2]	
Random effects model			0.0	[0.0; 0.5]	

Heterogeneity: $I^2 = 0.0\%$, $\tau^2 = 0$, $\chi_4^2 = 0.19$ ($p = 0.9959$)

GABABR antibodies(%)

eFigure 2e. Prevalence of AMPA receptor antibodies

eFigure 2f. Prevalence of Prevalence of CASPR antibodies

eFigure 2g. Prevalence of LGI1 antibodies

eFigure 2h. Prevalence of GAD65 antibodies

eFigure 2i. Prevalence of Abnormally Elevated Albumin

eFigure 2j. Prevalence of Type 5 Oligoclonal Bands

eFigure 2k. Prevalence of Type 3 Oligoclonal Bands

[Type here]

612   eFigure 2j. Prevalence of Elevated Protein

635 eFigure 3 Prevalence of Pleocytosis amongst studies with other WBC
636 cutoff values

637   A. Prevalence of Pleocytosis (WBC$\geq$5)

Study	Cases	Total	Prev(%)	95% C.I.
Maurus 2023	3	121	2.5	[0.4; 6.6]
Endres 2024	5	154	3.2	[1.4; 7.4]
Runge 2021	3	40	7.5	[3.3; 20.3]
Rattay 2021	8	98	8.2	[3.6; 14.8]
Du 2023	4	50	8.0	[3.6; 19.1]
Random effects model			**4.9**	**[2.5; 7.9]**

Heterogeneity: $I^2 = 36.4\%$, $\tau^2 = 0.0016$, $\chi^2_4 = 6.29$ ($p = 0.1786$)

Abnormal Cell Count (WBC>=5 cutoff)(%)

639   B. Prevalence of Pleocytosis combining studies with a WBC cutoff of WBC$\geq$5 and WBC >5
640   (i.e. abnormal as defined by the study, regardless of which WBC cutoff they used)

Study	Cases	Total	Prev(%)	95% C.I.
Lopes 2024	1	68	1.5	[0.7; 8.3]
Guasp 2021	2	105	1.9	[0.2; 6.3]
Jeppesen 2022	2	104	1.9	[0.7; 6.9]
Maurus 2023	3	121	2.5	[0.9; 7.1]
Endres 2024	5	154	3.2	[0.0; 5.0]
Endres 2015	6	179	3.4	[1.3; 6.9]
Gine-Serven 2022	3	95	3.2	[1.1; 8.9]
Campana 2022	11	314	3.5	[0.0; 0.0]
Oviedo-Salcedo 2018	6	124	4.8	[0.3; 7.7]
Runge 2022	5	100	5.0	[0.0; 7.4]
Runge 2021	3	40	7.5	[3.3; 20.3]
Rattay 2021	8	98	8.2	[4.3; 15.4]
Du 2023	4	50	8.0	[3.6; 19.1]
Kruse 2015 Group B	2	8	25.0	[10.9; 58.2]
Restrepo-Martinez 2020	5	14	35.7	[17.7; 60.8]
Kelleher 2020	1	2	50.0	[20.0; 80.0]
Kruse 2015 Group A	7	13	53.8	[30.3; 75.3]
Random effects model			**3.7**	**[1.7; 6.2]**

Heterogeneity: $I^2 = 68.4\%$, $\tau^2 = 0.0060$, $\chi^2_{16} = 50.59$ ($p < 0.0001$)

Abnormal Cell Count(%)

648 eFigure 4. MOOSE Checklist

Criteria	Brief Description of How Criteria were handled in the Meta-Analysis
Reporting of background should include	
Problem Definition	Patients presenting with first-episode psychosis may have an organic etiology identifiable using lumbar puncture. Detection of CSF abnormalities may help guide diagnosis and clinical management, thereby impacting prognosis. The proportion of patients with abnormalities in CSF remains unclear.
Hypothesis Statement	Since we didn't do a healthy control comparison what would the appropriate hypothesis statement be? CSF findings amongst patients with FEP will have a high enough prevalence to warrant inclusion in diagnostic workup.
Description of Study Outcomes	CSF abnormality
Type of Exposure or Intervention Used	n/a
Type of Study Designs Used	Prevalence
Study Population	Patients with first-episode psychosis
Reporting of Search Strategy should include	
Quality of Searchers	Academic qualifications listed on title page, all psychiatrists at major academic medical centers in the US and UK
Search Strategy, including time period included in the synthesis and key words	Full selection procedures with databases and search terms included in eMethods
Databases and registries searched	Ovid, MEDLINE, Embase, PsychINFO
Search Software used, name and version	Websites for each major database
Use of Hand Searching	Manually searched references of included articles

List of Citations located and those excluded, including justifications	Defined in Results
Method of Addressing Articles published in Languages other than English	Only studies in English were included although good-faith effort was made to screen and include non-English studies that fell within our eligibility criteria.
Method of Handling Abstracts and Unpublished Studies	Defined in Methods and eMethods
Reporting of Methods should Include	
Description of Relevance or Appropriateness of Studies Assembled for Assessing the Hypothesis to be tested	Described in Results, Study Selection. The minimum dataset to be included in the meta-analysis was the number of FEP patients with a CSF abnormality
Rationale for the selection and coding of data	Based on literature review and discussion with neurology and psychiatry experts
Assessment of confounding	Sensitivity analyses were performed to assess the impact of individual studies in pooled estimates
Assessment of study quality	Hoy et al. 2012's bias assessment
Assessment of heterogeneity	Calculated I^2
Description of statistical methods in sufficient detail to be replicated	Details provided in the methods section and supplement.
Provision of appropriate tables and graphics	Studies identified using PRISMA diagram. Forest plots provided. Raw data also included in supplement.
Reporting of results should include	
Graph summarizing individual study estimates and overall estimate	The results section includes forest plots for all analyses, as well as subgroup analyses and sensitivity analyses.

Table giving descriptive information for each study included	eTable 1
Results of sensitivity testing	
Quantitative assessment of bias	Bias assessment performed using Hoy et al 2012's checklist
Justification for Exclusion	The methods section references any studies excluded due to high risk of bias.
Assessment of Quality of Included Studies	Study quality reported in results.
Reporting of conclusions should involve	
Considerations of alternative explanations for observed results	Alternative explanations for observed results are detailed in the Discussion section.
Generalization of conclusions	Generalizability of our findings and clinical relevance are included in the Discussion.
Guidelines for future research	Directions for future research are discussed in the Discussion section
Disclosure of funding source	Defined on title page

657   eFigure 5 Prisma Checklist

Section and Topic	Item #	Checklist item	Location where item is reported
TITLE			
Title	1	Identify the report as a systematic review.	1
ABSTRACT			
Abstract	2	See the PRISMA 2020 for Abstracts checklist.	2
INTRODUCTION			
Rationale	3	Describe the rationale for the review in the context of existing knowledge.	2-3
Objectives	4	Provide an explicit statement of the objective(s) or question(s) the review addresses.	2
METHODS			
Eligibility criteria	5	Specify the inclusion and exclusion criteria for the review and how studies were grouped for the syntheses.	Supplement
Information sources	6	Specify all databases, registers, websites, organisations, reference lists and other sources searched or consulted to identify studies. Specify the date when each source was last searched or consulted.	3
Search strategy	7	Present the full search strategies for all databases, registers and websites, including any filters and limits used.	Supplement
Selection process	8	Specify the methods used to decide whether a study met the inclusion criteria of the review, including how many reviewers screened each record and each report retrieved, whether they worked independently, and if applicable, details of automation tools used in the process.	3, supplement
Data collection process	9	Specify the methods used to collect data from reports, including how many reviewers collected data from each report, whether they worked independently, any processes for obtaining or confirming data from study investigators, and if applicable, details of automation tools used in the process.	4
Data items	10a	List and define all outcomes for which data were sought. Specify whether all results that were compatible with each outcome domain in each study were sought (e.g. for all measures, time points, analyses), and if not, the methods used to decide which results to collect.	5
	10b	List and define all other variables for which data were sought (e.g. participant and intervention characteristics, funding sources). Describe any assumptions made about any missing or unclear information.	5
Study risk of bias assessment	11	Specify the methods used to assess risk of bias in the included studies, including details of the tool(s) used, how many reviewers assessed each study and whether they worked independently, and if applicable, details of automation tools used in the process.	5
Effect measures	12	Specify for each outcome the effect measure(s) (e.g. risk ratio, mean difference) used in the synthesis or presentation of results.	5
Synthesis methods	13a	Describe the processes used to decide which studies were eligible for each synthesis (e.g. tabulating the study intervention characteristics and comparing against the planned groups for each synthesis (item #5)).	5
	13b	Describe any methods required to prepare the data for presentation or synthesis, such as handling of missing summary statistics, or data conversions.	Supplement
	13c	Describe any methods used to tabulate or visually display results of individual studies and syntheses.	5
	13d	Describe any methods used to synthesize results and provide a rationale for the choice(s). If meta-analysis was performed, describe the model(s), method(s) to identify the presence and extent of statistical heterogeneity, and software package(s) used.	5
	13e	Describe any methods used to explore possible causes of heterogeneity among study results (e.g. subgroup analysis, meta-regression).	5, Supplement

	13f	Describe any sensitivity analyses conducted to assess robustness of the synthesized results.	5
Reporting bias assessment	14	Describe any methods used to assess risk of bias due to missing results in a synthesis (arising from reporting biases).	6, supplement
Certainty assessment	15	Describe any methods used to assess certainty (or confidence) in the body of evidence for an outcome.	5
RESULTS			
Study selection	16a	Describe the results of the search and selection process, from the number of records identified in the search to the number of studies included in the review, ideally using a flow diagram.	6
	16b	Cite studies that might appear to meet the inclusion criteria, but which were excluded, and explain why they were excluded.	6
Study characteristics	17	Cite each included study and present its characteristics.	6
Risk of bias in studies	18	Present assessments of risk of bias for each included study.	6
Results of individual studies	19	For all outcomes, present, for each study: (a) summary statistics for each group (where appropriate) and (b) an effect estimate and its precision (e.g. confidence/credible interval), ideally using structured tables or plots.	7-9, supplement
Results of syntheses	20a	For each synthesis, briefly summarise the characteristics and risk of bias among contributing studies.	6
	20b	Present results of all statistical syntheses conducted. If meta-analysis was done, present for each the summary estimate and its precision (e.g. confidence/credible interval) and measures of statistical heterogeneity. If comparing groups, describe the direction of the effect.	7-12
	20c	Present results of all investigations of possible causes of heterogeneity among study results.	12
	20d	Present results of all sensitivity analyses conducted to assess the robustness of the synthesized results.	Supplement
Reporting biases	21	Present assessments of risk of bias due to missing results (arising from reporting biases) for each synthesis assessed.	Supplement
Certainty of evidence	22	Present assessments of certainty (or confidence) in the body of evidence for each outcome assessed.	8-12
DISCUSSION			
Discussion	23a	Provide a general interpretation of the results in the context of other evidence.	13
	23b	Discuss any limitations of the evidence included in the review.	14
	23c	Discuss any limitations of the review processes used.	14
	23d	Discuss implications of the results for practice, policy, and future research.	15
OTHER INFORMATION			
Registration and protocol	24a	Provide registration information for the review, including register name and registration number, or state that the review was not registered.	5

	24b	Indicate where the review protocol can be accessed, or state that a protocol was not prepared.	PROSPERO website
	24c	Describe and explain any amendments to information provided at registration or in the protocol.	None
Support	25	Describe sources of financial or non-financial support for the review, and the role of the funders or sponsors in the review.	None
Competing interests	26	Declare any competing interests of review authors.	1
Availability of data, code and other materials	27	Report which of the following are publicly available and where they can be found: template data collection forms; data extracted from included studies; data used for all analyses; analytic code; any other materials used in the review.	Supplement

eTable 1. Study inclusion/exclusion criteria*direct quotes are denoted by quotation marks

Study	Recruitment setting	Patient Inclusion Criteria
Campana 2023	patients at tertiary care hospital in Department of Psychiatry and Psychotherapy LMU University Hospital	"Medical records of patients suggesting clinical signs of a possible underlying autoimmune encephalitis (based on careful screening of all available data on clinical and physical examinations) were excluded from our analysis."
Campana 2022	retrospective analysis from inpatients admitted to tertiary care hospital at Department of Psychiatry and Psychotherapy at LMU Munich selected for FEP patients	"Patients with clinical signs that could indicate the presence of an underlying autoimmune encephalitis (eg seizures, movement disorders, autonomic instability) were excluded based on thorough screening of all available data on clinical and physical examination."
Du 2023	patients hospitalized in Departments of Neurology and Psychiatry of Sichuan Provincial People's Hospital	"Patients with mild or non-severe COVID-19 who tested positive for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (antigen or nucleic acid test) before or after admission; patients who presented abnormal mental behavior on admission, with delusions, hallucinations, and confusion in speech, behavior, and thinking as the main clinical manifestations."

Endres 2017	patients at tertiary care hospital (Department of Psychiatry and Psychotherapy at University Medical Center Freiburg)	"Patients diagnosed with schizophreniform syndrome included those with schizophrenia (N=56), schizoaffective disorder (N=29), acute polymorphic psychotic disorder (N=14), and substance-induced psychosis (N=1). Only CSF/serum samples from patients with complete thyroid hormone status (thyroid-stimulating hormone [TSH], triiodothyronine [t3], and thyroxine [t4]) were included. For pragmatic reasons, we selected the first 100 patients since 2006. The study included 13 patients who underwent lumbar puncture between 2006 and 2009 (i.e., CSF analysis was performed if there were signs of possible neuroinflammatory features). The other 87 patients underwent lumbar puncture since June 2009, when CSF analysis was offered as a routine procedure."
Endres 2020	patients at tertiary care hospital (Department of Psychiatry and Psychotherapy at University Medical Center Freiburg)	"All inpatients with schizophreniform syndromes (according to the International Statistical Classification of Diseases and Related Health Problems criteria, unipolar depression following ICD-10: F32.X, F33.X, F06.3 and bipolar disorder following ICD- 10: F30.X, F31X, F06.3) who underwent an LP at the Department of Psychiatry and Psychotherapy were included.Other preexisting (e.g., earlier stroke) or newly described (e.g., migraine) neurological comorbidities were recorded but not considered as an exclusion criteria if the LP was performed within the diagnostic process of the psychiatric disorder."
Endres 2015	university clinic of psychiatry and psychotherapy Freiburg	"From 2006 to 2013, we acquired 180 CSF samples from psychotic patients. Between 2006 and 2009, CSF examinations were only performed in cases in which organic brain disease was suspected."
Endres 2024	all adult patients treated at specialized ward for psychosis and secondary mental disorders at University of Freiburg	"All adult patients treated in our specialized ward for psychosis and secondary mental disorders for over 2.5 years were screened, and those with primary or secondary psychotic syndromes were included in the current analysis(schizophreniform syndromes: F20.X, F29.X, F06.02, F10.5, F19.5; depression with psychotic symptoms: F32.3, F33.3; mania with psychotic symptoms: F30.2; bipolar affective disorder, currently manic or major depressive episode with psychotic symptoms: F31.2, F31.5). Thus, patients with secondary psychoses or rheumatological diseases were not excluded."
Gine-Serven 2022	acute inpatient units (adult or child and adolescent units) from the Department of Mental Health at the Hospital of Matar´o between 1 June 2018 and 31 March 2020 were offered to participate in the study	Patients with FEP who were admitted to acute inpatient units at the Hospital of Mataro between 1 June 2018 and 31 March 2020.

Guasp 2021	Hospital Cl´ınic Institut d'Investigacions Biom`ediques August Pi i Sunyer (IDIBAPS), University of Barcelona	"All patients with FEP admitted to 2 hospitals at University of Barcelona, between June 1, 2018, and March 31, 2020, were invited to participate in the study. FEP was defined as new-onset disorganized behavior accompanied by delusions or hallucinations."
Hinotsu 2022	newly hospitalized patients at Okayama Psychiatric Hospital initially diagnosed with schizophrenia, mood disorder, epilepsy, psychiatric symptoms	"Patients diagnosed with schizophrenia, a mood disorder or epilepsy with psychiatric symptoms"
Kelleher 2020	pts recruited from general psychiatric services from encatchment areas strictly defined as attached to St. Jame's hospital and Tallaght University Hospital in Dublin and Newcastle hospital Wicklow. FEP cases were recruited via community mental health teams who were educated about study and asked to recruit patients who met inclusion criteria. liased with neurology centres to identify any additional cases diagnosed with NMDA-R Ab encephalitis within encatchment area.Treatment resistant patients were invited by nursing staff from Clozapine clinics within encatchment area	"Inclusion criteria for the FEP cohort comprised of being resident in the study catchment area for longer than six months based on their ad- dress within the catchment area, being aged between 18 and 65 years old and to be experiencing their first episode of psychosis. Only 4 seropositive cases had an LP." Excluded: Presence of known pre- existing neurological disorder.
Kruse 2015 ANTI- NMDAR IgG seropositive	NMDA receptor IgG seropositive patients seen at Mayo Clinic rochester from 2009-2013	Group 2: NMDA receptor IgG. Retrospective assessment for each seropositive patient. "High likelihood assigned when new psychiatric symptoms of subacute onset were accompanied by at least one of the following: ew-onset movement disorder, encephalitic-appearing magnetic resonance imaging (MRI), encephalopathic or epileptiform elec- troencephalogram (EEG), inflammatory cerebrospi- nal fluid (CSF) (with protein exceeding 70 mg/dL, pleocytosis, or at least 4 CSF-exclusive oligoclonal bands), neural autoantibody at least 50% predictive for cancer (eMethods), or past episode of immuno- therapy-responsive encephalitis."
Kruse 2015	adult psychiatric inpatients at Mayo clinic who had comprehensive serological evaluation for neural autoantibodies	Group 1: adult psychiatric inpatients whose initial neuropsychiatric evaluation included comprehensive serologic evaluation for neural autoantibodies (January 1, 2002 - December 31, 2011)

Maurus 2023	FEP patients admitted to tertiary care hospital to Department of Psychiatry and Psychotherapy at University Hosital, Ludwig Maximilian University of Munich Germany	FEP admitted between 1 Jan 2008 and 1 Aug 2018 -Inclusion criteria were that patients have a main diagnosis of F2x (schizophrenia spectrum according to the ICD-10) in the discharge summary of the first in-patient stay, and that patients had undergone both a lumbar puncture and neurocognitive testing within the clinical routine assessments before receiving this diagnosis. In our hospital, CSF analyses are usually offered to every FEP patient by the treating physicians so as to rule out organic psychoses, according to best clinical practice. "We also included patients who initially presented themselves with psychotic symptoms and a non-F2x-diagnosis (e.g. drug-induced psychosis), and were later diagnosed within the schizophrenia spectrum. any psychiatric or physical pre- diagnoses possibly resulting in cognitive impairments or BBB dysfunction (such as intellectual disability, perinatal asphyxia or stroke); abnormal brain magnetic resonance imaging findings suggestive of a relevant co-occurring CNS disorder (e.g. neoplasms); and a time interval of more than 21 days between CSF and blood sampling, or of more than 90 days between CSF sampling and neurocognitive testing, to ensure a clinically meaningful temporal association. Based on thorough screening of all available data, 45 patients were excluded before data analysis."
Oviedo-Salcedo 2018	patients with schizophrenia who underwent a lumbar puncture through Department of Psychiatry and Psychotherapy at the Klinikum der Universitat Munchen	"We included patients with documented ICD-10 diagnoses of schizophrenia spectrum disorders and excluded patients with a diagnosis of organic psychotic disorders (F06.0/F06.1/F06.2), drug-induced psychotic disorder (F1X.5) or clinical signs that could indicate the presence of an underlying autoimmune encephalitis(e.g. seizures, move- ment disorders, autonomic instability), based on thorough screen- ing of all available data on clinical and physical examination. excluded patients with a diagnosis of organic psychotic disorders (F06.0/F06.1/F06.2), drug-induced psychotic disorder (F1X.5) or clinical signs that could indicate the presence of an underlying autoimmune encephalitis7 (e.g. seizures, movement disorders, autonomic instability), based on thorough screening of all available data on clinical and physical examination."
Oviedo-Salcedo 2021	screened clinical data from patient documentation of Department of Psychiatry and Psychotherapy at the University Hospital LMU Munich Germany	"Diagnoses were made in the clinical setting by the treating physicians according to the 10th version of the International classification of diseases manual (ICD-10). We included patients who were treated in our tertiary care hospital (Department of Psychiatry and Psychotherapy, University Hospital, LMU Munich, Munich, Germany) between July 2012 and May 2017 and who received a lumbar puncture with subsequent CSF diagnostics as part of the clinical routine. patients who had not received a CSF analysis in the past as part of the diagnostic work-up.
Restrepo-	Patients were recruited via in- and outpatient clinics in	"Patients who had not received a CSF analysis in the past as part of the diagnostic

Martinez 2020	the Capital Region of Denmark, whereas healthy controls were recruited via a Danish website (Forsøgsperson.dk). Patients and controls came from the same community. All participants had to be aged 18-50 years, and patients were to have been diagnosed with a nonorganic, nonaf- fective psychotic disorder (International Classification of Diseases, Tenth Revision (ICD10) F20/F22-29) within a year prior to inclusion.	work-up. Patients with organic psychotic disorders (ICD-10: F06.0/F06.1/F06.2) and substance-induced disorders (ICD-10: F1X.5) were excluded from our analyses in order to isolate cases of primary psychosis as defined by clinical judgment. We also screened for major neurological symptoms in the clinical documentation such as epileptic seizures and disturbed consciousness that could indicate a major neurological disease at the time of admission. The decision to perform the lumbar puncture was made by the treating physicians according to best clinical practice. In our psychiatric hospital, CSF analyses are usually offered to every FEP patient and to MEP patients who had not received a CSF analysis in the past as part of the diagnostic work-up."
Runge 2022	patients with schizophrenia spectrum disorders who were treated as inpatients in the Department of psychiatry and psychotherapy of the medical center of the University of Freiburg	Exclusion criteria: known substance use disorders and immunological disorders known for brain involvement.
Jeppesen 2022	Patients were recruited via in- and outpatient clinics in the Capital Region of Denmark, whereas healthy controls were recruited via a Danish website (Forsøgsperson.dk).	Patients and controls came from the same community. All participants had to be aged 18-50 years, and patients were to have been diagnosed with a non organic, non-affective psychotic disorder (International Classification of Diseases, Tenth Revision (ICD10) F20/F22-29) within a year prior to inclusion.
Runge 2021	patients with schizophrenia spectrum disorders who underwent LP during acute inpatient stay at University of Freiburg	Patients with Schizophrenia Spectrum Disorders who underwent lumbar puncture during their acute inpatient stay to exclude secondary organic causes of the disorder. They had to have received prior MRI imaging and be able to give consent. Patients with schizophrenia (ICD-10: F20), delusional disorders (ICD-10: F22), brief psychotic disorder (ICD-10: F23) and schizoaffective disorders (ICD-10: F25) were included. Patients with neurodegenerative diseases, acute clinical infections, or current substance dependence disorders, as well as neurological or immunological diseases with known brain involvement were excluded from the study.
Kranaster 2011	first episode schizophrenia or schizophreniform patients at University of Cologne according to DSM-IV criteria	no known previous or current treatment with antipsychotic medication

Steiner 2013	acutely ill patients from scientific blood bank at Magdeburg University Department of Psychiatry	"Patients with psychosis resulting from other medical conditions and substance-induced psychosis were excluded by a thorough physical examination, routine blood analysis (including differential blood cell count, kidney function tests, and levels of C-reactive protein, glucose, lipids, liver, enzymes, and thyroid hormones), screening for illegal drugs, And magnetic resonance imaging the brain. In Addition,electroencephalography (EEG)was performed.The same tests were carried out in the control, MD, and BLPD participants."
Srikanth 1994	patients admitted to NiMHANS Bangalore	"They met the exclusion criteria: absence of poor nutrition (based on general physical examination), anemia, generalized bacterial or fungal infections, recent trauma, alcohol and drug abuse, neurological disorders, therapeutic drugs (including psychotropic drugs) during the last 6 months. They never had organ transplantation, elec-electroconvulsive therapy (ECT), or recent vaccination or blood transfusion."
Seppala 2014	geriatric psychiatry department of Helsinki University Central Hospital consisting of 4 wards	"Psychotic symptoms had not lasted more than 2 years before their admission.No patients with a known diagnosis of dementia (AD, DLB, etc.) at admission were included. Patients with other diseases of the central nervous system (e.g., Parkinson disease [PD] or major stroke) were also excluded."
Bien 2021	pts recruited from two clinical sites with community service obligations for inpatient and outpatient services, including early recognition for psychosis units in Germany, Department of Psychiatry and Psychotherapy at University of Cologne, Department of Psychiatry and Psychotherapy at Central Institute of Mental Health Mannheim	"Individuals met the following criteria: attenuated positive symptoms, brief, limited intermittent psychotic symptoms that spontaneously resolved within a week, a recent decline in function."
Bauer 1987	patients were investigated at Department of Neurology and Psychiatry at Bundeswehrkrankenhaus Ulm	Only included patients newly diagnosed as schizophrenic
Rauber 2021	retrospective screening of local clinical patient database at University Clinic Munster, Germany to identify patients with available CSF data and primary psychotic disorders encompassing schizophrenia	Identified patients with available CSF mFC data and primary psychotic disorders encompassing schizophrenia, delusional disorders, acute and transient psychotic disorders or schizoaffective disorders.

Tang 2019	first episode psychosis patients recruited from institute of mental health, national neuroscience institute, a neurollogical center, and Tan Tock Seng Hospital, a general hospital in Singapore between September 2011 and October 2013	Inclusion criteria were age 16–50 years, the presence of less than 1 month of psychotic symptoms, and any of the following neurological symptoms: cognitive dysfunction,seizures, abnormal movements, or autonomic dysfunction. Patients were excluded if there was alcohol or drug-induced psychosis as determined by clinical history and/or a positive drug screen.
Rattay 2021	inpatients with psychosis with CSF analysis between 01/2016 and 06/2020 at Department of Psychiatry and Psychotherapy at University Hospital Tubingen Germany	Patients on any four of the acute admission wards or two wards specialized in the psychotherapy of psychotic disorders
Maier 2024	inpatients treated at the Department of Psychiatry, Social Psychiatry and Psychotherapy at Hannover Medical School	Patients with a previously diagnosed neurological or organic mental disorder (ICD-10: F00-F09), the second LP of the same patient, and CSF analysis that was not indicated for the differential diagnostic work-up of psychiatric symptoms were excluded.
Muller 1995	schizophrenic patients from 18 to 57 at the Psychiatric Hospital at University of Munich	Patients presenting a clinical indication for an lp, e.g. the first detailed investigation in order to exclude an organic disease, the first hospitaliza- tion, the first onset;first detailed investigation in order to exclude an organic disease, the first hospitalization
Theorell 2021	first episode patients were recruited from psychiatric wards and outpatient departments as a part of the Karolinska Schizophrenia Project	First-episode psychosis patients (n = 74), defined as first physician contact due to psychotic symptoms. Exclusion: overt abnormal signs on neurological examination, seizures, autonomic instability or a movement disorder.
Soderland		first-episode
Torrey 1978	first admission schizophrenia patients, multi-episode schizophrenia, schizo-affective psychosis, and manic depressive psychosis amongst inpatients at National Institute of Mental Health Bethesda. Controls were patients at National Naval medical center	"The patient group was those with first admission schizophrenia, multiple admission schizophrenia, schizo-affective psychosis and manic depressive psychosis. One control group were surgical patients with no known neurological or psychiatric disease. Finally there was another comparison group of 80 patients with neurological disease."

659
660
661
662 eTable2. Study Characteristics

Study	Year	Country	FEP (n)	Control (n)	Age (years)	Female (percent)	Psychosis Duration (weeks)	Quality Assessment
Campana et al.	2023	Germany	222	NA	34.89	46.4		8
Campana et al.	2022	Germany	314	NA	35.1	45.2	52.4	6
Du et al.	2023	China	57	NA				6

[Type here]

Endres et al.	2017	Germany	100	NA	33.32	59		6
Endres et al.	2020	Germany	279	NA	32.72	54		8
Endres et al.	2015	Germany	33	NA				7
Endres et al.	2024	Germany	161	NA	34.71	56		6
Gine-Serven et al.	2022	Spain	95	NA	35	39		9
Guasp et al.	2021	Spain	105	NA	30	42		8
Hinotsu et al.	2022	Japan	151	NA				9
Kelleher et al.	2020	Ireland	112	NA	33	38		7
Kruse et al.	2015	USA	13	173	27	92		6
Maurus et al.	2023	Germany	121		35.1	50	48.8	7
Oviedo-Salcedo et al.	2018	Germany	332		36.85	46.3	246.32	3
Oviedo-Salcedo et al.	2021	Germany	128		34.43	48.4	44.68	8
Restrepo-Martinez et al.	2020	Mexico	24		24.5	38.3	46.4	8
Runge et al.	2022	Germany	100	Pts with IIH	33.7	60		8
Jeppesen et al.	2024	Germany	104		26.1	38.5	86.8	7
Runge et al.	2021	Germany	40		34.6	60		7
Kranaster et al.	2011	Denmark	155		NA	0		8
Steiner et al.	2013	Germany	229	30 healthy controls	NA	0		6
Srikanth et al.	1994	India	35	35 controls (women undergoing epidural)	NA	0		6
Seppala et al.	2014	NA	51		NA	78		6

Bien et al.	2021	NA	103	Yes, 40 healthy controls	NA	19.1			9
Bauer et al.	1987	NA	15		NA	0			6
Rauber et al.	2021	NA	59	Control group with IIH 52 pts	NA	37			8
Tang et al.	2019	NA	15		NA	80			7
Rattay et al.	2021	Germany	144		NA				9
Maier et al.	2024	Germany	254		33.8	56.9	103.84		8
Muller et al.	1995	Germany							7
Theorell et al.	2021	Sweden and UK							8
Soderland et al.	2009	Sweden							8
Torrey et al.	1978	USA							6
Lopes et al.	2024	Portugal	68		49	60.3			7
Coughlin et al.	2016	USA	14		24	21	2.2		8

664 eTable 3. Protocol for how studies identified subgroups based off clinical suspicion for secondary
665 causes of psychosis

666 eTable 3a. Studies with low clinical suspicion for secondary causes

Study	Method of Rule Out	Additional Medical Tests performed	Serum studies (not used for inclusion/exclusion)	RBCs for Pleocytosis Correction	CSF Studies performed
Jeppesen 2022	Prior or current severe neurological disorder: head injury within past 3 months, epilepsy w/ seizures within past 10 years, multiple sclerosis, stroke, brain tumor.	In select cases additional neuroimaging, EEG were performed.	Serum and CSF performed.	Pleocytosis adjusted for RBC.	WBC, Albumin, Total Protein, IgG

	Per protocol, excluded known organic cause, or encephalitis but did not explicitly mention evaluation e.g. MRI, EEG, clinical exam for rule out. Did not a priori screen for or exclude infection.				
Guasp 2021	Exclusion: (1) positive symptoms of psychosis for >6 months, (2) previous diagnosis of intellectual disability (IQ), (3) any active medical or neurological conditions.	All patients had an MRI. EEG was routinely performed at one institution and if clinically indicated at another institution. Additionally had tox screen.	Serum samples for Nfl were obtained in addition to CSF studies performed	Unclear if RBC corrected. Did not explicitly mention.	NMDAR, Abnormal Celll Count
Endres 2020	Did not detail which specific tests were invoked. Did state that patients transferred from Dept of Neurology or those with dementia were excluded.	MRI and EEG performed on all patients	Anti-thyroid, antineuronal IgG, anti-NMDAR IgG, anti-VGKC, anti-neuronal IgG to Yo, Hu, CV2/CRMP5, Ri, Ma1/2, Sox1, GAD65, amphiphysin, Tr, Zic4, anti-MOG, anti-AQP4, WBC, Total Protein, Albumin Quotient, IgG index, OCBs in serum/CSF	Did correct for RBC contamination	WBC count, Elevated Protein, Oligoclonal Bands Type 2, Elevated Albumin, NMDAR, LGI1, CASPR, AMPAR, GABABR, IgG Index
Bien 2021	Neurological Exam, MRI brain, EEG, blood pathology all performed as a part of screening; Included only if EEG, MRI, serum studies and neurological exam were within normal limits.	All patients had already had MRI/EEG as a part of the screening process.	Serum and CSF	Did not mention RBC correction but also did not report out pleocytosis	NMDAR, GAD65, LGI1, CASPR, AMPAR, GABAR, Glycine
Gine-Serven 2022	Active medical or neurological diseases, did not detail method of assessment	Did not perform MRI/EEG	Serum and csf studies for neuronal antibodies	Did not include pleocytosis parameter	WBC, Protein, NMDAR, GAD65
Theorell 2021	Screened patients using neurological exam, screened out for seizures, autonomic instability or movement disorder but did not detail/explicitly invoke EEG/MRI	MRI performed in some patients. EEG not performed.	Serum and CSF performed	Did not mention RBC correction, but also did not report pleocytosis	NMDAR

[Type here]

Rauber 2021	Patients were exlcuded if: Signs of systemic infection. 2. Suspected viral encephalitis and bacterial meningitis assessed by an elevated CSF cell count (>5/µl), detection of viruses (Herpes simplex virus-1/2 [HSV-1/HSV-2], Cytomegalovirus [CMV], Epstein-Barr virus [EBV], Varicella zoster virus [VZV], Human herpesvirus-6 [HHV-6], and Enterovirus) in the CSF by polymerase-chain-reaction or bacteria by gram staining.	There was a separate NMDARE cohort who was diagnosed using the following criteria: : a rapid onset (<3 month) of four out of six typical clinical symptoms, either abnormal EEG or pleocytosis/ oligoclonal bands in CSF studies, exclusion of differential diagnoses and detection of CSF-IgG antibodies targeting the GluN1 subunit of the NMDA receptor.	Serum and CSF studies	Did not explicitly report out pleocytosis	NMDAR, GAD65, LGI1, CASPR, AMPAR, GABAR, Glycine, Yo, Hu
Runge 2021	Neurodegenerative diseases, clinical infections, and neurological diseases with brain involvement were all excluded. Any patients with abnormality on MRI were excluded.	All patients had MRI and EEG.	Serum and CSF	Did not report pleocytosis and therefore did not comment on RBC correction	WBC, Protein, Oligoclonal Bands Type 2, NMDAR, GAD65, LGI1, CASPR, AMPAR, GABABR, IgG,
Kelleher 2020	Neurology review, MRI brain, EEG were used for exclusion. Presence of a pre-existing neurological disorder resulted in exclusion.	All patients were offered EEG, MRI, malignancy screen (pelvic or testicular US & X-ray), and lumbar puncture for CSF	Serum and CSFstudies performed	Did not mention RBC correction for pleocytosis	WBC, Protein, NMDAR
Campana 2023	Clinical and physical Examinations for seizures, movement disorders, autonomic instability were utilized for exclusion.	MRI offered to all patients. EEG was not offered.	Serum and CSF studies performed	Did not mention RBC correction for pleocytosis.	Oligoclonal bands Type 2, Oligoclonal Bands Type 3
Campana 2022	Clinical and Physical Examinations for signs that could indicate presence of an autoimmune encephalitis e.g. seizures, movement disorders, autonomic instability were utilized for exclusion. Did not screen for infection.	All patients underwent an MRI.	Serum and CSF studies performed	Did not mention RBC correction for pleocytosis.	WBC, OCB2, OCB3, OCB4, OCB5, Albumin, MZRZ,
Muller 1997	Patients presenting with clinical indication for LP, first	MRI and EEG not performed.	Serum and CSF studies performed	Did not test for pleocytosis	Elevated Protein, elevated albumin, elevated IgG index

	onset, and first hospitalization for psychosis were included. MRI and EEG not used for rule out.				
Coughlin 2016	Patients were excluded if: (1) history of neurological disorder, structural brain abnormality or history of traumatic brain injury with loss of consciousness; (2) history of special education or known learning disability; (3) history of an inflammatory medical condition including but not limited to diabetes, human immunodeficiency virus and/or hepatitis; (4) benzodiazepine use in the past 6 months; (5) substance abuse (for example, cannabis, alcohol) in the previous 6 months or any history of substance dependence except for nicotine; (6) contraindication to participation in magnetic resonance imaging (MRI); or (7) contraindication to participation in PET including pregnancy.	All patients underwent MRI.	Did not perform CSF studies	Did not assess pleocytosis	IL6
Srikanth 1994	Did not mention MRI or EEG	exclusion criteria: absence of poor nutrition (based on general physical examination), anemia, generalized bacterial or fungal infections, recent trauma, alcohol and drug abuse, neurological disorders, therapeutic drugs (including psychotropic drugs) during the last 6 months. They never had organ transplantation, elec-troconvulsive therapy (ECT), or	Serum and CSF	Did not mention RBC correction/did not calculate pleocytosis	Examined for infection e.g. CMV, HSV1, measles, mumps, varicella, JEV

		recent vaccination or blood transfusion.			

672   eTable 3b. Studies with a population enriched for high clinical suspicion for secondary causes of psychosis
673

Lopes 2024	Patients were all from a neurology unit: first psychotic episode with atypical features as late-onset psycho sis and psychosis refractory to treatment. MRI and EEG data were included where possible from review of medical records but not used for exclusion. All patients met possible, probable, or definite AIP by two neurologists utilizing the diagnostic criteria set by the 2019 Consensus	All had EEG and MRI	Serum and CSF where possible	Did not mention RBC correction	WBC, protein, OCB2, NMDAR, GAD65, LGI1, CASPR
Tang 2019	Included if there were the following neurological symptoms: cognitive function, seizures, abnormal movements, or autonomic dysfunction. CT or MRI was performed on all patients, but not both, not used for rule in/out.	Cases that were positive for anti-NMDAR or anti-VGKC encephalitis were offered MRIs. One was explicitly noted to have EEG.	Serum and CSF	Did not mention RBC correction for pleocytosis	NMDAR antibodies
Steiner 2013	Psychosis resulting from other medical conditions, and substance induced psychosis were excluded by a thorough physical examination, routine blood analysis, drug screen, MRI and EEG.	All patients had blood tests, MRI, and EEG.	Serum and CSF studies were performed	Did not mention RBC correction for pleocytosis	NMDAR antibodies
Restrepo-Martinez 2020	Patients were selected as high probability for ANDMARE according to the Graus et al. criteria.	MRI and EEG were obtained in all patients.	Serum studies not reported.	Did not report pleocytosis and therefore did not comment on RBC correction	Patients were screened for infection, namely HIV, M. TB, cryptococcus neoformans, viral PCR for Herpes Type 1 and Type 2, CMV, EBV, Varicella-Zoster, HHV 6, 7, 8, Enterovirus,

					Parvovirus B19, lymphocytic choriomeningitis virus
Kruse 2015 Group A	One of the following: new-onset movement disorder, encephalitic MRI, EEG, CSF findings, past episode of immuno-therapy responsive encephalitis were used for rule out. One subgroup of patients defined as Group 2/Group A was comprised of patients who had serum positivity for anti-NMDAR antibodies.	All patients had MRI, EEG and serum tests.	Serum and CSF	Did not mention RBC correction	WBC, Elevated Protein, Oligoclonal Bands Type 2,NMDAR antibodies
Du 2023	High risk given acute psychosis in the context of Covid-19. The exclusion criteria were as follows: (1) patients without COVID-19; (2) patients with psy chotic symptoms related to other systemic diseases (such as hepatic encephalopathy, renal encephalopathy, pulmonary encephalopathy, and hyponatremia), encephalitis, dementia, poisoning, drug abuse, or steroid use; (3) patients with severe or critical pneumonia; and (4) patients who were missing much critical data.	All patients had an EEG and MRI.	Serum and CSF	Did not mention RBC correction	Screened for Covid-19, WBC, Elevated Protein
Rattay 2021	Exclusion diagnostics of alcohol-/drug-associated, systemic, or other brain organic causes are based on a physical examination, neuropsychological testing, routine blood testing, urine drug screening, breath/blood alcohol test, electroencephalography (EEG), and brain structural imaging (MRI) at initial manifestation.	serum, MRI, EEG	Serum and CSF	Did not mention RBC correction	WBC, Protein, Oligoclonal Bands Type 2,Oligoclonal Bands Type 3, Oligoclonal Bands Type 4, NMDAR antibodies, anti-Yo, anti-Hu
Kruse 2015 Group B	Inclusion was One of the following: new-onset movement disorder,encephalitic MRI, EEG, CSF findings, past episode of immuno-therapy responsive encephalitis	All patients had MRI, EEG and serum tests.	Serum and CSF	Did not mention RBC correction	Did not mention screening for infection

[Type here]

eTable 3c. Studies with an undifferentiated sample in terms of suspicion for secondary causes of psychosis

Endres 2015	MRI and EEG performed for all patients	MRI, EEG, serum	Serum and CSF	Did not mention RBC correction	Cell count, protein, oligoclonal bands type 2, Oligoclonal bands Type 3, Oligoclonal Bands Type 4, Oligoclonal Bands Type 5, Elevated Albumin
Maier 2024	EEG, MRI and or CT	EEG, MRI or CT, serum studies	Serum and CSF studies	Did not mention RBC correction	Screened for infectious encephalitis e.g. HSV, enterovirus, neuroborreliosis, meningoencephalitis, CMV
Soderland 2009	Did not mention EEG or MRI For screening	No mention of other tests e.g. MRI, EEG.	Did not mention serum studies	Did not mention RBC correction	Did not explicitly screen for infections/CNS infections
Seppala 2014	All patients had MRI or CT. Excluded stroke, Parkinson's disease but no further exclusion criteria. Did not mention EEG	All patients had either MRI or CT.	Did not mention serum studies	Did not mention RBC correction	Tau, AB42
Kranaster 2011	Did not mention MRI or EEG	None	Did not mention serum studies	Did not mention RBC correction or pleocytosis	total cell count, total protein, ratios of albumin, IgG, IgM, IgA, and glucose, oligoclonal bands, lactate, and antibody indices of neurotrophic viruses as well as Toxoplasma gondii and Borrelia burgdorferi
Runge 2022	The information about diagnosis and comorbidity came from chart review. Patients with neurodegenerative diseases, acute clinical infections, or current substance dependence disorders, as well as neurological or immunological diseases with known brain involvement were	Patients had previously undergone MRI and EEG.	Serum and CSF	Did not mention RBC correction or pleocytosis	WBC, protein, oligoclonal bands type 2, NMDAR, GAD65, LGI1, CASPR, AMPAR, IgG, Herpes virus, EBV, CMV, Toxoplasma gondii

	excluded from the study.				
Hinotsu 2022	disorders including neuroleptic malignant syndrome were excluded.	MRI and EEG	Serum and CSF	Did not mention RBC correction	Screened for prior infection. CSF studies:
Endres 2017	Only CSF/serum samples from patients with complete thyroid hormone status (thyroid stimulating hormone [TSH], triiodothyronine [t3], and thy roxine [t4]) were included.	MRI and EEG	Serum and CSF	No RBC correction/pleocytosis reporting	WBC, protein
Torrey 1978	Did not explicitly screen out	MRI and EEG not performed.	Serum and CSF studies performed	Did not assess for pleocytosis	Measles, HSV-1, CMV, rubella, IgG, IgA
Endres 2024	Patients with secondary or rheumatological causes were not excluded.	All patients were offered MRI and EEG but not used for exclusion	Serum and CSF studies performed	Did not assess for pleocytosis	Abnormal cell count, abnormal protein, oligoclonal bands Type 2, elevated albumin, NMDAR, elevated IgG, MOG

685
686

687 **eTable 4a Comparison of prevalence of CSF abnormalities between the two methods of**
688 **handling the partial tandem overlap of patient cohorts in Enders 2015-2024**

CSF Abnormality	Including Endres 2015, and 2022 + 2024 (merged study)	Including Endres 2020
AB42	31.4% (19.3–44.9)	31.4% (19.3–44.9)
AMPAR	0.0% (0.0–0.5)	0.0% (0.0–0.3)
Abnormal Cell Count (>5 cells)	3.2% (2.1–4.4)	3.1% (2.0–4.4)
Abnormal Cell Count (>/=5 cells)	4.9% (2.5–7.9)	5.0% (2.8–7.8)
Abnormal Protein Baseline	18.7% (9.7–29.5)	17.1% (8.2–28.0)
Albumin	18.7% (14.9–22.7)	17.6% (13.5–22.1)
Anti-CASPR	0.0% (0.0–0.6)	0.0% (0.0–0.3)
Anti-GABABR	0.0% (0.0–0.5)	0.0% (0.0–0.3)
Anti-GAD65	0.0% (0.0–0.6)	0.0% (0.0–0.9)
Anti-Glycine	0.0% (0.0–1.1)	0.0% (0.0–1.1)
Anti-Hu	0.2% (0.0–1.3)	0.0% (0.0–1.2)
IL1B	42.3% (23.8–61.9)	42.3% (23.8–61.9)
IgG index	5.4% (1.1–11.6)	5.2% (0.4–13.5)
Anti-LGI1	0.0% (0.0–0.6)	0.0% (0.0–0.3)
MZRZ	0.7% (0.0–2.9)	0.7% (0.0–2.9)
Anti-NMDA	2.3% (0.1–5.8)	2.6% (0.1–7.2)
Oligoclonal Bands Type 2	6.5% (3.4–10.6)	7.1% (3.2–12.0)
Oligoclonal Bands Type 3	6.6% (4.3–9.3)	7.6% (5.4–10.1)
Oligoclonal Bands Type 4	9.6% (3.1–19.0)	14.8% (12.0–17.8)
Oligoclonal Bands Type 5	0.0% (0.0–0.4)	0.0% (0.0–0.4)
Pressure	16.0% (7.0–27.6)	16.0% (7.0–27.6)
Tau	21.6% (11.2–34.0)	21.6% (11.2–34.0)
Anti-Yo	0.4% (0.0–1.7)	0.0% (0.0–0.9)

689 % prevalences as estimated by the random effects model

691 **eTable 4b Comparison of subgroup-prevalence of clinically relevant CSF abnormalities**
692 **between the two methods of handling the partial tandem overlap of patient cohorts in**
693 **Enders 2015-2024**

CSF Abnormality	Subgroup (by Suspicion for Secondary Causes)	Including Endres 2015 and 2022+2024 (Merged)	Including Endres 2020
Anti-NMDAR antibodies	Low suspicion	0.0%	0.0%
	High suspicion	23.1%	23.1%
	Undifferentiated	2.1%	2.6%
Pleocytosis	Low suspicion	3.1%	3.1%
	High suspicion	3.3%	3.1%
	Undifferentiated	3.2%	NA
OCB2	Low suspicion	9.7%	8.6%
	High suspicion	13.8%	13.8%
	Undifferentiated	6.6%	7.1%

% prevalences as estimated by the random effects model

Acknowledgements:

Thank you to Tim W. Rattay, MD and Dirk Wildgruber, MD for generously providing
further detail of the FEP patients with CSF results from Rattay et. al, 2021, to enable
those patients to be included in this meta-analysis.

<u>References</u>

1. Perälä J, Suvisaari J, Saarni SI, et al. Lifetime prevalence of psychotic and bipolar I disorders
in a general population. *Arch Gen Psychiatry*. 2007;64(1):19-28.
doi:10.1001/archpsyc.64.1.19

2. Blackman G, Byrne R, Gill N, et al. How common is secondary psychosis? Estimates from a
systematic review and meta-analysis. *World Psychiatry Off J World Psychiatr Assoc WPA*.
2025;24(1):145-146. doi:10.1002/wps.21292

3. Guasp M, Gine-Serven E, Maudes E, et al. Clinical, Neuroimmunologic, and CSF
Investigations in First Episode Psychosis. *Neurology*. 2021;97(1):e61-e75.

4. Graus F, Titulaer MJ, Balu R, et al. A clinical approach to diagnosis of autoimmune
encephalitis. *Lancet Neurol*. 2016;15(4):391-404. doi:10.1016/S1474-4422(15)00401-9

5. Husari KS, Dubey D. Autoimmune Epilepsy. *Neurother J Am Soc Exp Neurother*.
2019;16(3):685-702. doi:10.1007/s13311-019-00750-3

6. Basu B, Abboud H. The Use of APE2 Score to Diagnose Autoimmune Encephalitis.
Neurology. 2024;103(7_Supplement_1).

7. Pollak TA, Lennox BR, Müller S, et al. Autoimmune psychosis: an international consensus on
an approach to the diagnosis and management of psychosis of suspected autoimmune
origin. *Lancet Psychiatry*. 2020;7(1):93-108. doi:10.1016/S2215-0366(19)30290-1

8. Herken J, Prüss H. Red Flags: Clinical Signs for Identifying Autoimmune Encephalitis in
Psychiatric Patients. *Front Psychiatry*. 2017;8:25. doi:10.3389/fpsyt.2017.00025

9. Dubey D, Pittock SJ, McKeon A. Antibody Prevalence in Epilepsy and Encephalopathy score:
Increased specificity and applicability. *Epilepsia*. 2019;60(2):367-369. doi:10.1111/epi.14649

10.   Endres D, Meixensberger S, Dersch R, et al. Cerebrospinal fluid, antineuronal
autoantibody, EEG, and MRI findings from 992 patients with schizophreniform and affective
psychosis. *Transl Psychiatry*. 2020;10(1):279. doi:10.1038/s41398-020-00967-3

11.   Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated
guideline for reporting systematic reviews. *BMJ*. 2021;372:n71. doi:10.1136/bmj.n71

12.   Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of Observational Studies in
EpidemiologyA Proposal for Reporting. *JAMA*. 2000;283(15):2008-2012.
doi:10.1001/jama.283.15.2008

13.   Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic
reviews and meta-analyses: the PRISMA statement. *BMJ*. 2009;339:b2535.
doi:10.1136/bmj.b2535

14.   DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials*.
736   1986;7(3):177-188. doi:10.1016/0197-2456(86)90046-2

737   15.   Schmid CH, Lau J, McIntosh MW, Cappelleri JC. An empirical study of the effect of the
738   control rate as a predictor of treatment efficacy in meta-analysis of clinical trials. *Stat Med*.
739   1998;17(17):1923-1942.   doi:10.1002/(sici)1097-0258(19980915)17:17%3C1923::aid-
740   sim874%3E3.0.co;2-6

741   16.   Bauer K, Kornhuber J. Blood-cerebrospinal fluid barrier in schizophrenic patients. *Eur*
742   *Arch Psychiatry Neurol Sci*. 1987;236(5):257-259.

743   17.   Bien CG, Rohleder C, Mueller JK, Bien CI, Koethe D, Leweke FM. Neural
744   Autoantibodies in Cerebrospinal Fluid and Serum in Clinical High Risk for Psychosis, First-
745   Episode Psychosis, and Healthy Volunteers. *Front Psychiatry Front Res Found*.
746   2021;12:654602.

747   18.   Campana M, Lohrs L, Straus J, et al. Blood-brain barrier dysfunction and folate and
748   vitamin B12 levels in first-episode schizophrenia-spectrum psychosis: a retrospective chart
749   review. *Eur Arch Psychiatry Clin Neurosci*. 2023;273(8):1693-1701.

750   19.   Campana M, Straus J, Munz S, et al. Cerebrospinal Fluid Pathologies in Schizophrenia-
751   Spectrum Disorder-A Retrospective Chart Review. *Schizophr Bull*. 2022;48(1):47-55.

752   20.   Coughlin JM, Wang Y, Ambinder EB, et al. In vivo markers of inflammatory response in
753   recent-onset schizophrenia: a combined study using [(11)C]DPA-713 PET and analysis of
754   CSF and plasma. *Transl Psychiatry Psychiatry*. 2016;6:e777.

755   21.   Du J, Zhou X, Guo Y, Jiang F, Yan M, Zhu Q. Clinical Features and Prognosis of
756   Coronavirus Disease 2019-Related Psychosis: A Retrospective Case Series. *Alpha*
757   *Psychiatry*. 2023;24(6):276-282.

758   22.   Endres D, Dersch R, Hochstuhl B, et al. Intrathecal Thyroid Autoantibody Synthesis in a
759   Subgroup of Patients With Schizophreniform Syndromes. *J Neuropsychiatry Clin Neurosci*.
760   2017;29(4):365-374.

761   23.   Endres D, Perlov E, Baumgartner A, et al. Immunological findings in psychotic
762   syndromes: a tertiary care hospital's CSF sample of 180 patients. *Front Hum Neurosci*.
763   2015;9. doi:10.3389/fnhum.2015200476

764   24.   Endres D, Runge K, Meixensberger S, et al. An observational study on the association
765   of anti-thyroid autoantibodies with clinical, EEG, MRI, FDG-PET, cerebrospinal fluid and anti-
766   neuronal antibody findings in 530 patients with schizophreniform and affective disorders.
767   *Psychoneuroendocrinology*. 2021;131:105320.

768   25.   Endres D, von Zedtwitz K, Matteit I, et al. Spectrum of Novel Anti-Central Nervous
769   System Autoantibodies in the Cerebrospinal Fluid of 119 Patients With Schizophreniform and
770   Affective Disorders. *Biol Psychiatry*. 2022;92(4):261-274. doi:10.1016/j.biopsych.2022.02.010

771   26.   Endres D, von Zedtwitz K, Nickel K, et al. Association of rheumatological markers with
772   neuronal antibodies, cerebrospinal fluid, electroencephalography, and magnetic resonance

imaging findings in 224 patients with psychotic syndromes. *Brain Behav Immun*.
2024;119:482-493. doi:10.1016/j.bbi.2024.04.001

27. Gine-Serven E, Martinez-Ramirez M, Boix-Quintana E, et al. Routine cerebrospinal fluid
parameters as biomarkers in first-episode psychosis: A prospective observational study. *Prog*
Neuropsychopharmacol Biol Psychiatry. 2022;112:110424.

28. Guasp M, Martin-Aguilar L, Sabater L, et al. Neurofilament Light Chain Levels in Anti-
NMDAR Encephalitis and Primary Psychiatric Psychosis. *Neurology*. 2022;98(14):e1489-
e1498.

29. Hinotsu K, Miyaji C, Yada Y, et al. The validity of atypical psychosis diagnostic criteria to
detect anti-NMDA receptor encephalitis with psychiatric symptoms. *Schizophr Res*.
2022;248:292-299.

30. Jeppesen R, Borbye-Lorenzen N, Christensen RHB, et al. Levels of cytokines in the
cerebrospinal fluid of patients with psychotic disorders compared to individually matched
healthy controls. *Brain Behav Immun*. 2024;117:167-174.

31. Jeppesen R, Nilsson AC, Sorensen NV, Orlovska-Waast S, Christensen RHB, Benros
ME. Antineuronal antibodies in cerebrospinal fluid and serum of 104 patients with psychotic
disorders compared to 104 individually matched healthy controls. *Schizophr Res*.
2023;252:39-45.

32. Jeppesen R, Orlovska-Waast S, Sørensen NV, Christensen RHB, Benros ME.
Cerebrospinal Fluid and Blood Biomarkers of Neuroinflammation and Blood-Brain Barrier in
Psychotic Disorders and Individually Matched Healthy Controls. *Schizophr Bull*.
2022;48(6):1206-1216. doi:10.1093/schbul/sbac098

33. Kelleher E, McNamara P, Dunne J, et al. Prevalence of N-Methyl-d-Aspartate Receptor
antibody (NMDAR-Ab) encephalitis in patients with first episode psychosis and treatment
resistant schizophrenia on clozapine, a population based study. *Schizophr Res*.
2020;222:455-461.

34. Kranaster L, Koethe D, Hoyer C, Meyer-Lindenberg A, Leweke FM. Cerebrospinal fluid
diagnostics in first-episode schizophrenia. *Eur Arch Psychiatry Clin Neurosci*.
2011;261(7):529-530.

35. Kruse JL, Lapid MI, Lennon VA, et al. Psychiatric autoimmunity: N-methyl-d-aspartate
receptor IgG and beyond. *Psychosom J Consult Liaison Psychiatry*. 2015;56(3):227-241.
doi:10.1016/j.psym.2015.01.003

36. Lopes J, Malaquias MJ, Freitas J, et al. Blood and CSF anti-neuronal antibodies testing
in psychotic syndromes: a retrospective analysis from a tertiary psychiatric hospital. *Immunol*
Res. 2024;31:31.

37. Maier HB, Stadler J, Deest-Gaubatz S, et al. The significance of cerebrospinal fluid
analysis in the differential diagnosis of 564 psychiatric patients: Multiple sclerosis is more
common than autoimmune-encephalitis. *Psychiatry Res*. 2024;333:115725.

38.   Maurus I, Wagner S, Campana M, et al. The relationship between blood-brain barrier
dysfunction and neurocognitive impairments in first-episode psychosis: findings from a
retrospective chart analysis. *BJPsych Open*. 2023;9(3):e60.

39.   Miller C, Kirchmair R, Troger J, et al. CSF of neuroleptic-naive first-episode
schizophrenic patients: levels of biogenic amines, substance P, and peptides derived from
chromogranin A (GE-25) and secretogranin II (secretoneurin). *Biol Psychiatry*.
1996;39(11):911-918. doi:10.1016/0006-3223(95)00098-4

40.   Oviedo-Salcedo T, Wagner E, Campana M, et al. Cerebrospinal fluid abnormalities in
first- and multi-episode schizophrenia-spectrum disorders: impact of clinical and
demographical variables. *Transl Psychiatry Psychiatry*. 2021;11(1):621.

41.   Oviedo-Salcedo T, de Witte L, Kumpfel T, et al. Absence of cerebrospinal fluid
antineuronal antibodies in schizophrenia spectrum disorders. *Br J Psychiatry*.
2018;212(5):318-320.

42.   Müller N, Ackenheil M. Immunoglobulin and albumin content of cerebrospinal fluid in
schizophrenic patients: relationship to negative symptomatology. *Schizophr Res*.
1995;14(3):223-228. doi:10.1016/0920-9964(94)00045-a

43.   Rattay TW, Martin P, Vittore D, et al. Cerebrospinal fluid findings in patients with
psychotic symptoms-a retrospective analysis. *Sci Rep*. 2021;11(1):7169.

44.   Rauber S, Heming M, Repple J, et al. Cerebrospinal fluid flow cytometry distinguishes
psychosis spectrum disorders from differential diagnoses. *Mol Psychiatry*. 2021;26(12):7661-
7670.

45.   Restrepo-Martinez M, Ramirez-Bermudez J, Bayliss L, Espinola-Nadurille M.
Characterisation and outcome of neuropsychiatric symptoms in patients with anti-NMDAR
encephalitis. *Acta Neuropsychiatr*. 2020;32(2):92-98.

46.   Runge K, Balla A, Fiebich BL, et al. Antibody indices of infectious pathogens from serum
and cerebrospinal fluid in patients with schizophrenia spectrum disorders. *Fluids Barriers*
CNS. 2022;19(1):61.

47.   Runge K, Fiebich BL, Kuzior H, et al. An observational study investigating cytokine
levels in the cerebrospinal fluid of patients with schizophrenia spectrum disorders. *Schizophr*
Res. 2021;231:205-213. doi:10.1016/j.schres.2021.03.022

48.   Seppälä TT, Louhija UM, Appelberg B, Herukka SK, Juva K. Comparison between
clinical diagnosis and CSF biomarkers of Alzheimer disease in elderly patients with late onset
psychosis: Helsinki old age psychosis study (HOPS). *Am J Geriatr Psychiatry*.
2014;22(9):908-916. doi:10.1016/j.jagp.2012.08.020

49.   Severance EG, Gressitt KL, Alaedini A, et al. IgG dynamics of dietary antigens point to
cerebrospinal fluid barrier or flow dysfunction in first-episode schizophrenia. *Brain Behav*
Immun. 2015;44:148-158. doi:10.1016/j.bbi.2014.09.009

50.   Söderlund J, Schröder J, Nordin C, et al. Activation of brain interleukin-1beta in
schizophrenia. *Mol Psychiatry*. 2009;14(12):1069-1071. doi:10.1038/mp.2009.52

51.   Srikanth S, Ravi V, Poornima KS, Shetty KT, Gangadhar BN, Janakiramaiah N. Viral
antibodies in recent onset, nonorganic psychoses: correspondence with symptomatic
severity. *Biol Psychiatry*. 1994;36(8):517-521.

52.   Steiner J, Walter M, Glanz W, et al. Increased prevalence of diverse N-methyl-D-
aspartate glutamate receptor antibodies in patients with an initial diagnosis of schizophrenia:
Specific relevance of IgG NR1a antibodies for distinction from N-methyl-D-aspartate
glutamate receptor encephalitis. *JAMA Psychiatry*. 2013;70(3):271-278.
doi:10.1001/2013.jamapsychiatry.86

53.   Tang C, Tan K, Lim G, et al. N-Methyl-D-Aspartate(NMDA) Receptor and Voltage-Gated
Potassium Channel (VGKC) Antibody-Associated Encephalitides Presenting as First Episode
Acute Psychosis. *Front Psychiatry Front Res Found*. 2019;10:913.

54.   Theorell J, Ramberger M, Harrison R, et al. Screening for pathogenic neuronal
autoantibodies in serum and CSF of patients with first-episode psychosis. *Transl Psychiatry*.
2021;11(1):566.

55.   Toorey EF, Peterson MR, Brannon WL, Carpenter WT, Post RM, Van Kammen DP.
Immunoglobulins and viral antibodies in psychiatric patients. *Br J Psychiatry*. 1978;132:342-
348. doi:10.1192/bjp.132.4.342

56.   Jarius S, Pache F, Körtvelyessy P, et al. Cerebrospinal fluid findings in COVID-19: a
multicenter study of 150 lumbar punctures in 127 patients. *J Neuroinflammation*.
2022;19(1):19. doi:10.1186/s12974-021-02339-0

57.   Gresa-Arribas N, Titulaer MJ, Torrents A, et al. Antibody titres at diagnosis and during
follow-up of anti-NMDA receptor encephalitis: a retrospective study. *Lancet Neurol*.
2014;13(2):167-177. doi:10.1016/S1474-4422(13)70282-5

58.   Abboud H, Probasco JC, Irani S, et al. Autoimmune encephalitis: proposed best practice
recommendations for diagnosis and acute management. *J Neurol Neurosurg Psychiatry*.
2021;92(7):757-768. doi:10.1136/jnnp-2020-325300

59.   Rozenberg A, Shelly S, Vaknin-Dembinsky A, et al. Cognitive impairments in
autoimmune encephalitis: the role of autoimmune antibodies and oligoclonal bands. *Front
Immunol*. 2024;15:1405337. doi:10.3389/fimmu.2024.1405337

60.   Blackman G, Neri G, Al-Doori O, et al. Prevalence of Neuroradiological Abnormalities in
First-Episode Psychosis: A Systematic Review and Meta-analysis. *JAMA Psychiatry*.
2023;80(10):1047-1054. doi:10.1001/jamapsychiatry.2023.2225

61.   Tu LH, Malhotra A, Sheth KN, Yaesoubi R, Forman HP, Venkatesh AK. Yield of Head
Computed Tomography Examinations for Common Psychiatric Presentations and
Implications for Medical Clearance From a 6-Year Analysis of Acute Hospital Visits. *JAMA
Intern Med*. 2022;182(8):879-881. doi:10.1001/jamainternmed.2022.2198

62.   Skikic M, Arriola JA. First Episode Psychosis Medical Workup: Evidence-Informed
Recommendations and Introduction to a Clinically Guided Approach. *Child Adolesc Psychiatr
Clin N Am*. 2020;29(1):15-28. doi:10.1016/j.chc.2019.08.010

63.   Endres D, Matysik M, Feige B, et al. Diagnosing Organic Causes of Schizophrenia
Spectrum Disorders: Findings from a One-Year Cohort of the Freiburg Diagnostic Protocol in
Psychosis (FDPP). *Diagnostics*. 2020;10(9). doi:10.3390/diagnostics10090691

64.   Kular S, Griffin K, Batty R, Hoggard N, Connolly D. The role of MRI and CT of the brain
in first episodes of psychosis and behavioural abnormality. *Clin Radiol*. 2021;76(9):712.e9-
712.e13. doi:10.1016/j.crad.2021.05.009

65.   Peskind E, Nordberg A, Darreh-Shori T, Soininen H. Safety of lumbar puncture
procedures in patients with Alzheimer's disease. *Curr Alzheimer Res*. 2009;6(3):290-292.
doi:10.2174/156720509788486509

66.   de Almeida SM, Shumaker SD, LeBlanc SK, et al. Incidence of post-dural puncture
headache in research volunteers. *Headache*. 2011;51(10):1503-1510. doi:10.1111/j.1526-
4610.2011.01959.x

67.   Al-Hashel J, Rady A, Massoud F, Ismail II. Post-dural puncture headache: a prospective
study on incidence, risk factors, and clinical characterization of 285 consecutive procedures.
BMC Neurol. 2022;22(1):261. doi:10.1186/s12883-022-02785-0

68.   Bodilsen J, Mariager T, Vestergaard HH, et al. Association of Lumbar Puncture With
Spinal Hematoma in Patients With and Without Coagulopathy. *JAMA*. 2020;324(14):1419-
1428. doi:10.1001/jama.2020.14895

69.   Nath S, Koziarz A, Badhiwala JH, et al. Atraumatic versus conventional lumbar puncture
needles: a systematic review and meta-analysis. *The Lancet*. 2018;391(10126):1197-1204.
doi:10.1016/S0140-6736(17)32451-0

70.   Endres D, Matysik M, Feige B, et al. Diagnosing Organic Causes of Schizophrenia
Spectrum Disorders: Findings from a One-Year Cohort of the Freiburg Diagnostic Protocol in
Psychosis (FDPP). *Diagnostics*. 2020;10(9):691. doi:10.3390/diagnostics10090691

71.   Aldayel AY, Alharbi MM, Almasri MS, Alkhonezan SM. Public knowledge and attitude
toward lumbar puncture among adults in Riyadh, Saudi Arabia: A cross-sectional study.
SAGE Open Med. 2019;7:2050312119871066. doi:10.1177/2050312119871066

72.   Ross EL, Becker JE, Linnoila JJ, Soeteman DI. Cost-Effectiveness of Routine Screening
for Autoimmune Encephalitis in Patients With First-Episode Psychosis in the United States. *J
Clin Psychiatry*. 2020;82(1):19m13168. doi:10.4088/JCP.19m13168

73.   Campana M, Yakimov V, Moussiopoulou J, et al. Association of symptom severity and
cerebrospinal fluid alterations in recent onset psychosis in schizophrenia-spectrum disorders
– An individual patient data meta-analysis. *Brain Behav Immun*. 2024;119:353-362.
doi:10.1016/j.bbi.2024.04.011

74.   Cullen AE, Palmer-Cooper EC, Hardwick M, et al. Influence of methodological and
patient factors on serum NMDAR IgG antibody detection in psychotic disorders: a meta-
analysis of cross-sectional and case-control studies. *Lancet Psychiatry*. 2021;8(2):109-120.
doi:10.1016/S2215-0366(20)30432-6

[Type here]

75.   Milano C, Businaro P, Papi C, et al. Assessing Commercial Tissue-Based Assays for
Autoimmune Neurologic Disorders (I). *Neurol Neuroimmunol Neuroinflammation*.
12(4):e200410. doi:10.1212/NXI.0000000000200410

76.   Papi C, Milano C, Arlettaz L, et al. Assessing Commercial Tissue-Based Assays for
Autoimmune Neurologic Disorders (II). *Neurol Neuroimmunol Neuroinflammation*.
12(4):e200406. doi:10.1212/NXI.0000000000200406

77.   Hoy D, Brooks P, Woolf A, et al. Assessing risk of bias in prevalence studies:
modification of an existing tool and evidence of interrater agreement. *J Clin Epidemiol*.
2012;65(9):934-939. doi:10.1016/j.jclinepi.2011.11.014

78.   Egger M, Smith GD, Schneider M, Minder C. Bias in meta-analysis detected by a simple,
graphical test. *BMJ*. 1997;315(7109):629. doi:10.1136/bmj.315.7109.629

79.   Blackman G, Neri G, Al-Doori O, et al. Prevalence of Neuroradiological Abnormalities in
First-Episode Psychosis: A Systematic Review and Meta-analysis. *JAMA Psychiatry*.
2023;80(10):1047-1054. doi:10.1001/jamapsychiatry.2023.2225

948